Belgian Week of Gastroenterology

Belgian Week of 

Gastroenterology 

ANTWERP Hilton, March 4 - 6, 2010 

www.belgianweek.be or www.bwge.be 

Thursday 4 FrIday 5 saTurday 6

Thursday 4 

FrIday 5 

saTurday 6 

WElcomE aDDrEss 

dear colleagues, 

i would like to invite you at our 22nd Belgian Week of gastroenterology taking 

place from March 4 to 6, 2010 in the beautiful city of antwerp. 

last year was a big success and as we do not have many options in Belgium for 

good locations for such a congress (599 participants in 2008; 628 in 2009), we 

preferred to come back to the hilton hotel in 2010. Perhaps we shall change 

the location in 2011. 

this year we received 279 abstracts from all the research groups and joint meeting. 

it is my pleasure to invite you to the friday night dinner and Party on March 5 

at the appelmans Brasserie, nearby the hilton hotel. 

on saturday we will have the seven societies symposium organised by the 

Vlaamse Vereniging van gastroenterologie with the topic: “over and Under 

nutrition”. this year, in parallel with the seven societies symposium, the 

Pathology club is organising «the President’s day» for the emeritate of Prof. 

karel geboes. 

antwerp is a fantastic city with lots of points of interest and nice shopping 

facilities. a list of suggested social activities is available on our website. 

i would like to thank all scientifi c committees and biomedical partners for their 

support in organising this Belgian Week of gastroenterology 2010. 

isabelle colle 

scientifi c coordinator 

All abstracts of lectures will be published in Acta Gastroenterologica Belgica. 

Acta Gastroenterologica is accessible on internet : 

www.acta-gastroenterologica.be 

P. Michielsen, Editor in chief 

P. Stärkel, Deputy Editor 

2 XXII nd • Belgian Week of gastroenterology • antWerP, March 4-6 2010

Thursday 4 

FrIday 5 

saTurday 6 

INDEX 

WelcoMe address 2 

general inforMation 6 

steering coMMittee 7 

inVited lectUres 8 

satellite syMPosia 10 

thUrsday March 4 : 

Basl / Blic 12 

og – fWo 14 

Belgian Pancreatic clUB 16 

sMall BoWel groUP 17 

Joint Meeting : session a 18 

Joint Meeting : session B 19 

iBd 20 

Belgian hP stUdy groUP 21 

Basl Poster session 22 

PrograM oVerVieW 24 

friday March 5 : 

Joint Meeting : session c 26 

Joint Meeting : Plenary session d 27 

Joint Meeting : Plenary session e 28 

Joint Meeting : session f 29 

Bgdo / radiology / Pathology 30 


Bsgie / BesPghan 33 

nUtrition groUP 34 

Poster sessions : 

satUrday March 6 : 

Joint Meeting 36 

Bsgie 37 

iBd 37 

7 societies syMPosiUM : 

« over and under nutrition» 38 

gi Pathology clUB : 

« the President’s day» 40 

friday night Party 43 

take Me to hilton antWerP 44 

BWg 2010 Partners 48 

XXII nd • Belgian Week of gastroenterology • antWerP, March 4-6 2010 

5 


Thursday 4 

FrIday 5 

saTurday 6 

gENEral INformatIoN 

AccreditAtion 

certificates for accreditation will be provided at the end of each 1/2 day session (3cP units) to the 

registered delegates who have attended the respective sessions. (type-rubriek 3, cP18, organizer 

2730, Belgian Week of gastroenterology) 

LAnguAge 

dutch, french and english. english (British spelling) for abstracts, slides and announcements. 

AbstrActs 

authors were invited to send abstracts through the congress website until november 30th and to choose either the 

« Joint Meeting » (clinical and Basic research with clinical impact) or the appropriate research groups. 

106 abstracts were submitted to the Joint meeting and in total we received 279 abstracts, research groups included! 

the Joint Meeting oral presentations were selected by the Joint Meeting selection committee and will be presented 

on thursday afternoon and on friday. the research groups oral presentations were selected by the selection 

committee of each group. 

for the Joint Meeting, the abstracts were scored anonyMoUsly from 0 to 10, on the basis of originality and 

scientific value by each of the members of the selection committee. it gathers experts in the different fields of gastroenterology. 

the abstracts were then separated into several categories, the highest scores being presented during 

the Plenary session on friday morning and friday afternoon, in increasing order of scores. 

Prizes will be awarded on saturday morning for the two best oral presentations at the Joint Meeting in Basic 

research and clinical research. the Bgdo will also present an award for the best communication in oncology. 

the best iBd abstract will be awarded by both iBd patient associations. on thursday noon, 2 Basl prizes will be 

awarded at the end of the morning session for the best basic & clinical oral presentation in hepatology. 

venue 

hilton antwerp hotel – groenplaats – 2000 antwerp 

tel: +32 3 204 12 12 / fax: +32 3 204 86 88. 

the conference centre has separate elevators to access from the lobby of the hotel. 

the 3rd floor is the main floor of the congress where you will find: the registration, some conference 

rooms and the exhibition room. 

PArking 

here are the closest parkings to the hilton antwerp : 

- groenplaats Parking: the hilton antwerp has reserved 200 places for our congress. 

- Meir Parking. 

- Brabo Parking. 

- lombardia Parking. 

event coordinAtor 

anne-france de Meyer – 102, av. J&P carsoel – 1180 Brussels 

tel : +32 2 375 36 26 / fax : +32 2 375 47 84 / e-mail : anne.france.de.meyer@skynet.be 

HoteL rooms At tHe HiLton 

Please contact anne-france de Meyer. 

type room single double 

hilton guest 199 € 219 € 

deluxe 249 € 259 € 

executive 279 € 289 € 

AntwerP tourism office 

tourism antwerp – grote Markt, 13 – 2000 antwerp 

tel : +32 3 232 01 03 / e-mail : visit@antwerpen.be 


stEErINg commIttEE 

Scientific co o r d i n at o r 

o f t h e Jo i n t Me e t i n g 

isabelle colle 

Se v e n SocietieS 

g. d’haens, g. Van assche 

(VVge, Vlaamse Vereniging voor gastro-enterologie) 

J.l. Van laetheM, J.c. deBongnie 

(srBge, société royale Beige de gastro-entérologie) 

P. dePreZ, P. Van der sPek 

(Bsgie, Belgian society of gastrointestinal endoscopy) 

a. de rooVer, J. lerUt, 

J. M. collard (UPPer g.i section), 

P. Pattyn (colo-rectal section), 

r. troisi (hBP section) 

(rBss, royal Belgian society of surgery) 

B. oP de Beeck, e. danse 

(srBr-kBVr, royal Belgian society of radiology, 

digestive radiology and abdominal imaging) 

J. delWaide, h. reynaert 

(Basl, Belgian association for the study of the liver) 

J.l. Van laetheM, e. VancUtseM 

(Bgdo, Belgian group of digestive oncology) 

re S e a r c h gr o u p S 

i. dePoortere, B. de Winter 

(og-fWo, gastro-intestinal regulatory mechanisms) 

k. geBoes, a. JoUret-MoUrin 

(gastro-intestinal Pathology club) 

g. VeereMan, i. hoffMan 

(Be sPghan, Belgian society for Paediatric 

gastroenterology, hepatology and nutrition) 

a. Van gossUM 

(sBnc, société Belge de nutrition clinique) 

d. yseBaert 

(VVkVM, Vlaamse Vereniging voor klinische 

Voeding en Metabolisme) 

Scientific Se c r e ta r i e S o f t h e 

Se v e n SocietieS Sy M p o S i uM 

Martin hiele (VVge) 

geert d’haens (VVge) 

e. loUis, s. VerMeire 

(Belgian iBd research group) 

M. delhaye 

(BPc, Belgian Pancreatic club) 

V. laMy, f. Mana 

(BhPsg, Belgian helicobacter Pylori study group) 

d. UrBain 

(Belgian small Bowel group) 

J. Pirenne, h. Van VlierBerghe 

(Blic, Belgian liver intestine committee) 

P. flaMen, l. carP 

(nUclear Medicine) 


7 


Thursday 4 

FrIday 5 

saTurday 6 

INvItED lEcturEs 

Thursday 4 

Basl / BlIc : room lijn 

12h15 : apoptosis, from bench to bedside. 

M. BilodeaU / Montreal, canada 

og-fWo : room teun 

09h00 : Pharmacology of inflammatory visceral pain. 

P. holZer / austria 

11h00 : Pharmacotherapy in somatic pain research. 

g. hans / antwerp - Belgium 

BElgIaN PaNcrEatIc cluB : room sancy 

09h00 : Pathophysiology of inflammatory pancreatic 

diseases and its clinical implications. 

J.l. frossard / geneva, switzerland 

11h15 : screening individuals for pancreatic cancer: 

for whom? how? when? and how frequently? 

P. dePreZ / Brussels 

JoINt mEEtINg BElgIaN WEEk : room lijn 

15h00 : m. Hautekeete lecture : sepsis and cirrhosis. 

J.l. Vincent / (erasme, Brussels) 

og-fWo : room teun 

14h00 : Development of postinflammatory animal 

models and visceral hyperalgesia. 

n. Vergnolle / france 

HP grouP : room tiffany 

14h00 : the diagnosis of resistance of H. pylori by other methods 

than culture: what, how, costs and availability. 

V.y. MiendJe deyi / Brussels 

IBD grouP : room sancy 

14h00 : Er stress and autophagy. 

a. kaser / austria 

15h05 : Impaired autophagy in crohn’s disease: 

an opened gate to invasive bacteria? 

a. darfeUille - MichaUd / france 

16h00 : crohn’s disease: th17 and/or th1 disease? 

s. Brand / germany 

17h05 : tNfdeltaarE mice: a model to study EIms in cD. 

d. eleWaUt / ghent 


FrIday 5 

BgDo / raDIology : room sancy 

09h30 : radionucleide therapy for primary liver tumors. 

B. laMBert / UZ gent 

09h50 : sIrt: Nuclear medicine considerations 

and pitfalls. 

P. flaMen / Bordet, Brussels 

10h10 : angiographic considerations in patients 

undergoing liver-directed therapies. 

g. MaleUX / UZ leuven 

12h00 : radionucleide therapy for Neuroendocrine tumors: indications and pitfalls. 

c. de roose / UZ leuven 

BgDo / PatHology : room sancy 

14h00 : Emphasis on the key role of the pathologist in kras mutation testing in the selection 

of patients for Egfr-targeted therapy in colorectal cancer. 

a. hoorens / UZ Brussels 

16h00 : Diagnostic algorithm of lynch syndroom. 

h. Vasen / leiden, the netherlands 

saTurday 6 

sEvEN socIEtIEs symPosIum: ovEr aND uNDEr NutrItIoN 

room teun/lijn 

see all invited lectures page : 38 

gI PatHology cluB: tHE PrEsIDENt’s Day 

room sancy/tiffany 

see all invited lectures page : 40 


9 


Thursday 4 

FrIday 5 

saTurday 6 

satEllItE symPosIa 

Thursday MarCh 4 

room teun 

13h15-14h00 BayEr 

«controversies in the treatment of Hepatocellular carcinoma» 

speakers : c. Verslype (UZ leuven) / i. Bobarth (Ucl st luc) 

room teun 

17h30-18h15 MOVETIs 

« the clinical dilemma of chronic constipation: 

prucalopride a new way out?» 

speakers: h. Piessevaux (Ucl st luc) / J. tack (kUleuven) / M. Van outryve (UZ antwerpen) 

room teun 

18h15-19h00 GILEad 

« long-term efficacy of tenofovir monotherapy for hepatitis B 

virus-monoinfected patients after failure of nucleoside/nucleotide 

analogues.» 

speakers: f. van Bömmel (Berlin, germany) 

FrIday MarCh 5 

room teun / LiJn 

13h15-14h00 sOLVay 

«Exocriene pancreatic insufficiency: different tests and outcome» 

speakers: k. Verbeke (kUleuven) / M. delhaye (UlB erasme) 


17h30-18h15 sChErING PLOuGh 

«mucosal Healing : the corner stone of the IBD battle» 


18h15-19h00 MENarINI 

oBIs study: use of Psychomedicine in case of IBs 

speaker: B. fischler (UlB saint-Pierre) 

use of musculotrope spasmolytica: lesson from the oBIs study 

speaker: J. tack (kUleuven) 

Interest in food guidelines in case of IBs 

speaker: h. Piessevaux (Ucl st luc) 


One liver. One life. One VIREAD 

P.P. 416,75 € 

NAME OF THE MEDICINAL PRODUCT Viread 245 mg fi lm-coated tablets QUALITATIVE AND QUANTITATIVE COMPOSITION Each fi lm-coated tablet contains 245 mg of tenofovir disoproxil (as fumarate), equivalent to 

300 mg of of tenofovir disoproxil fumarate, or 136 mg of tenofovir. Excipient(s): Excipient(s): Each tablet contains 153.33 mg lactose monohydrate. For a full list of excipients, see section 6.1.PHARMACEUTICAL FORM Film-coated 

tablet. tablet. Light blue, almond-shaped, fi lm-coated tablets, debossed on on one one side with the markings “GILEAD” and and “4331” and and on on the other side with the the marking “300”. CLINICAL PARTICULARS Therapeutic indications 

HIV-1 infection: Viread is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults over 18 years of age. The demonstration of benefi t of Viread in HIV-1 infection is 

based on results results of one study study in in treatment-naïve patients, including patients with a high viral load (> (> 100,000 copies/ml) and and studies in which Viread was added to stable background therapy (mainly tritherapy) in 

antiretroviral pre-treated patients experiencing early virological failure (< 10,000 copies/ml, with the majority of patients having having < < 5,000 copies/ml). The choice of Viread Viread to treat antiretroviral experienced patients with with 

HIV-1 infection should be based on individual viral resistance testing and/or treatment history of patients. Hepatitis B infection: Viread is indicated for the treatment of chronic hepatitis B in adults with compensated liver 

disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active infl ammation and/or fi brosis. This indication is based on histological, 

virological, biochemical and serological responses mainly in adult nucleoside-naïve patients with HBeAg positive and HBeAg negative chronic hepatitis B with compensated liver function. Posology and method of 

administration Therapy should be initiated by a physician experienced in the management of HIV infection and/or treatment of chronic hepatitis B. In exceptional circumstances in patients having particular diffi culty in 

swallowing, Viread can be administered following disintegration of the tablet in at least 100 ml of water, orange juice or grape juice. Adults: The recommended dose for the treatment of HIV or for the treatment of 

chronic hepatitis B is 245 mg (one tablet) once daily taken orally with food. Chronic hepatitis B: The optimal duration of treatment is unknown. Treatment discontinuation may be considered as follows:- In HBeAg positive 

patients without cirrhosis, treatment should be administered for at least 6-12 months after HBe seroconversion (HBeAg loss and HBV DNA loss with anti-HBe detection) is confi rmed or until HBs seroconversion or there 

is loss of effi cacy (see section 4.4). Serum ALT and HBV DNA levels should be followed regularly after treatment discontinuation to detect any late virological relapse. - In HBeAg negative patients without cirrhosis, 

treatment should be be administered at least until HBs HBs seroconversion or there is evidence of loss of effi cacy. With prolonged treatment for more than 2 years, regular reassessment is recommended recommended to confi rm that 

continuing the selected therapy remains appropriate for the patient. Paediatric patients: Viread is not recommended for use in children below the age of 18 years due to insuffi cient data on safety and effi cacy 

(see section 5.2). Elderly: No data are available on which to make a dose recommendation for patients over the age of 65 years (see section 4.4). Renal insuffi ciency: 

Tenofovir is eliminated by renal excretion and the 

exposure to tenofovir increases in patients with renal dysfunction. There are limited data on the safety and effi cacy of tenofovir disoproxil fumarate in patients with moderate and severe renal impairment (creatinine 

clearance < 50 ml/min) and long term safety data has not been evaluated for mild renal impairment (creatinine clearance 50-80 ml/min). Therefore, in patients with renal impairment tenofovir disoproxil fumarate should 

only be used if the potential benefi ts of treatment are considered to outweigh the potential risks. Dose interval adjustments are recommended for patients with creatinine clearance < 50 ml/min. Mild renal impairment 

(creatinine clearance 50-80 ml/min): Limited data from clinical studies support once daily dosing of tenofovir disoproxil fumarate in patients with mild renal impairment. Moderate renal impairment (creatinine clearance 

30-49 ml/min): Administration of 245 mg tenofovir disoproxil (as fumarate) every 48 hours is recommended based on modelling of single-dose pharmacokinetic data in non-HIV and non-HBV infected subjects with 

varying degrees of renal impairment, including end-stage renal disease requiring haemodialysis, but has not been confi rmed in clinical studies. Therefore, clinical response to treatment and renal function should be closely 

monitored in these patients (see sections 4.4 and 5.2). Severe renal impairment (creatinine clearance < 30 ml/min) and haemodialysis patients: Adequate dose adjustments cannot be applied due to lack of alternative tablet 

strengths, therefore use in this group of patients is not recommended. If no alternative treatment is available, prolonged dose intervals may be used as follows: Severe renal impairment: 245 mg tenofovir disoproxil (as 

fumarate) may be administered every 72-96 hours (dosing twice a week). Haemodialysis patients: 245 mg tenofovir disoproxil (as fumarate) may be administered every 7 days following completion of a haemodialysis 

session*. These dose adjustments have not been confi rmed in clinical studies. Simulations suggest that the prolonged dose interval is not optimal and could result in increased toxicity and possibly inadequate response. 

Therefore clinical response to treatment and renal function should be closely monitored (see sections 4.4 and 5.2). * Generally, Generally, once weekly dosing assuming three haemodialysis sessions per week, each of approximately 

4 hours duration or after 12 hours cumulative haemodialysis. No dosing recommendations can be given for non-haemodialysis patients with creatinine clearance < 10 ml/min. Hepatic impairment: 

No dose adjustment 

is required in patients with hepatic impairment (see sections 4.4 and 5.2). If Viread is discontinued in patients with chronic hepatitis B with or without HIV co-infection, these patients should be closely monitored for 

evidence of exacerbation of hepatitis (see section 4.4). Contraindications Hypersensitivity to the active substance or to any of the excipients. Undesirable effects HIV-1: 

Assessment of adverse reactions from clinical 

study data is based on experience in two studies in 653 treatment-experienced patients receiving treatment with tenofovir disoproxil fumarate (n = 443) or placebo (n = 210) in combination with other antiretroviral 

medicinal products for 24 weeks and also in a double-blind comparative controlled study in which 600 treatment-naïve patients received treatment with tenofovir disoproxil 245 mg (as fumarate) (n = 299) or stavudine 

(n = 301) in combination with lamivudine and efavirenz for 144 weeks. Approximately one third of patients can be expected to experience adverse reactions following treatment with tenofovir disoproxil fumarate in 

combination with other antiretroviral agents. These reactions are usually mild to moderate gastrointestinal events. The adverse reactions with suspected (at least possible) relationship to treatment are listed below by 

body system organ class and absolute frequency. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Frequencies are defi ned as very common ( (≥ 1/10) or common 

(≥ 1/100, < 1/10). See also Post-marketing experience below. 

Metabolism and nutrition disorders: Very common: hypophosphataemia Nervous system disorders: Very common: dizziness 

Gastrointestinal disorders: Very 

common: diarrhoea, vomiting, nauseaCommon: fl atulence Approximately 1% of tenofovir disoproxil fumarate-treated patients discontinued treatment due to the gastrointestinal events. Combination antiretroviral therapy 

has has been been associated with metabolic abnormalities such as as hypertriglyceridaemia, hypertriglyceridaemia, hypercholesterolaemia, insulin resistance, hyperglycaemia hyperglycaemia and hyperlactataemia (see section 4.4). Combination Combination antiretroviral therapy has 

been associated with redistribution of of body fat (lipodystrophy) in in HIV patients patients including the loss of peripheral and facial subcutaneous fat, increased intra-abdominal and visceral fat, breast hypertrophy and dorsocervical 

dorsocervical 

fat accumulation (buffalo hump). In a 144-week controlled clinical study in antiretroviral-naïve patients that compared tenofovir disoproxil fumarate with stavudine in combination with lamivudine and efavirenz, patients 

who received tenofovir disoproxil had a signifi cantly lower incidence of lipodystrophy compared with patients who received stavudine. The tenofovir disoproxil fumarate arm also had signifi cantly smaller mean increases 

in fasting triglycerides and total cholesterol than the comparator arm. In HIV infected patients with severe immune immune defi ciency at at the time of initiation of combination antiretroviral therapy (CART), an infl infl ammatory reaction 

to asymptomatic or residual opportunistic infections may arise (see section 4.4). Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or 

long-term exposure to to combination antiretroviral therapy (CART). The frequency of this is is unknown (see section 4.4). Hepatitis B: Assessment of adverse reactions from clinical study data is primarily based on experience 

in in two double-blind comparative controlled studies (GS-US-174-0102 and GS-US-174-0103) in in which 641 patients patients with chronic hepatitis hepatitis B and compensated liver disease received treatment with tenofovir disoproxil 

245 mg (as fumarate) daily (n = 426) or adefovir dipivoxil 10 mg daily (n = 215) for 48 weeks. The adverse reactions with suspected (at least possible) relationship to treatment are listed below by body system organ 

class and frequency. Frequencies are defi ned as common (≥ 1/100, < 1/10). See also Post-marketing experience below. 

Nervous system disorders:Common: disorders: disorders:Common: headache 

Gastrointestinal disorders: Common: diarrhoea, 

vomiting, abdominal pain, nausea, abdominal distension, fl atulence Hepatobiliary disorders: Common: ALT increase General disorders and administration site conditions: 

Common: fatigue Treatment beyond 48 weeks: 

Continued treatment with tenofovir disoproxil fumarate for 96 weeks, in studies GS-US-174-0102 and GS-US-174-0103, did not reveal any new adverse reactions and no change in the tolerability profi le (nature or severity 

of adverse events). Exacerbations during treatment: In studies with nucleoside-naïve patients, on-treatment ALT elevations > 10 times ULN (upper limit of normal) and > 2 times baseline occurred in 2.6% of tenofovir 

disoproxil fumarate-treated patients versus 1.9% of adefovir dipivoxil-treated patients. Among tenofovir disoproxil fumarate-treated patients, on-treatment ALT elevations had a median time to onset of 8 weeks, resolved 

with continued treatment, and, in a majority of cases, were associated with a ≥ 2 log copies/ml reduction in viral load that preceded or coincided with the ALT elevation. Periodic monitoring of hepatic function is 

10 

recommended during treatment. Post-marketing experience: In addition to adverse reaction reports from clinical studies the following possible adverse reactions have also been identifi ed during post-marketing safety 

surveillance of tenofovir disoproxil fumarate. Frequencies are defi ned as rare (≥ 1/10,000, < 1/1,000) or very rare (< 1/10,000) including isolated reports. Because these events have been reported voluntarily from a 

population of unknown size, estimates of frequency cannot always be made. Metabolism and nutrition disorders: Rare: lactic acidosis Not known: hypokalaemia 

Respiratory, thoracic and mediastinal disorders: Very rare: 

dyspnoea Gastrointestinal disorders: Rare: pancreatitis 

Hepatobiliary disorders: 

Rare: increased transaminases Very rare: hepatitis Not known: hepatic steatosis 

Skin and subcutaneous tissue disorders: Rare: rash 

Musculoskeletal and connective tissue disorders: 

Not known: rhabdomyolysis, osteomalacia (manifested as bone pain and infrequently contributing to fractures), muscular weakness, myopathy 

Renal and urinary 

disorders:Rare: Rare: acute renal failure, renal failure, proximal renal tubulopathy (including Fanconi syndrome), increased creatinine Very rare: acute tubular necrosis Not known: nephritis (including acute interstitial nephritis), 

nephrogenic diabetes insipidus General disorders and administration site conditions: Very rare: asthenia The following adverse reactions, listed under the body system headings above, may occur as a consequence of 

proximal renal tubulopathy: rhabdomyolysis, osteomalacia (manifested as bone pain and infrequently contributing to fractures), hypokalaemia, muscular weakness, myopathy and hypophosphataemia. These events are 

not considered to be causally associated with tenofovir disoproxil fumarate therapy in the absence of proximal renal tubulopathy. In HBV infected patients, clinical and laboratory evidence of exacerbations of hepatitis have 

occurred after discontinuation of HBV therapy (see section 4.4). MARKETING AUTHORISATION HOLDER Gilead Sciences International Limited, Cambridge CB21 6GT, United Kingdom MARKETING AUTHORISATION 

NUMBER(S) EU/1/01/200/001 EU/1/01/200/002 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of fi rst authorisation: 5 February 2002 Date of last renewal: 7 February 2007 DATE OF 

REVISION OF THE TEXT 04/2009 Medicinal product subject to medical prescription €416,75 (€0,00), (€0,00) 

• It is recommended that creatinine clearance is calculated in all patients prior to initiating therapy with Viread. • Renal function (creatinine clearance and serum phosphate) 

should be monitored every four weeks during the fi rst year and then every three months.• Viread should only be used in patients with impaired renal function if the potential 

benefi ts of treatment are considered to outweigh the potential risks.• For patients with creatinine clearance of < 50 ml/min, adjustment in the dosing interval for Viread 

would be required as per the SPC. Viread is not recommended for patients with severe renal impairment (creatinine clearance < 30 ml/min). • Viread should be avoided with 

concurrent adefovir dipivoxil or concurrent /recent use of a nephrotoxic medicinal product due to the increased risk of renal adverse reactions. 

090529/16

Thursday 4 

room «LiJn» Basl / BlIc 

• 

sEssION 1 

moDErators : s. BOurGEOIs, P. dELTENrE 

08.30 A01 characterization of the liver progenitor cell niche in liver diseases; 

potential involvement of WNt and NotcH signaling. 

B. spee (1), g. carpino (2), B. schotanus (3), a. katoonizadeh (1), s. Vanderborght (1), 

e. gaudio (4), t. roskams (1) / [1] kUleuven, [2] University of rome, italy, [3] Utrecht 

University, netherlands, [4] sapienza University, rome, italy 

08.42 A02 Presence of liver angiogenesis and upregulation of the vascular 

endothelial growth factor (vEgf) in a mice model of non-alcoholic 

steatohepatitis (NasH). 

s. coulon, a. geerts, B. Brouwers, d. Vlaeminck, l. libbrecht, c. Van steenkiste, 

f. heindryckx, h. Van Vlierberghe, i. colle / UZ gent 

08.54 A03 activation of the liver progenitor cell compartment is not sufficient 

to ensure liver regeneration. 

a.c. dusabineza, J. abarca-Quinones, n. Van hul, i. leclercq / Ucl saint-luc 

09.06 A07 angiogenic changes in a new mouse model for hepatocellular 

carcinoma assessed with state-of-the-art imaging technology. 

f. heindryckx (1), B. Vandeghinste (1), n. charette (2), d. slaets (1), l. libbrecht (1), 

c. casteleyn (1), s. staelens (1), P. starkel (2), a. geerts (1), i. colle (1), 

h. Van Vlierberghe (1) / [1] UZ gent, [2] Ucl saint-luc 

09.18 A04 N-glycosylation patterns in Hcc-mice chronically injected with DEN 

and their evolution after treatment with anti-Plgf. 

B. Blomme, f. heindryckx, i. colle, J.M. stassen, n. callewaert, h. Van Vlierberghe / 

UZ gent 

09.30 A05 glycogen synthase kinase 3 (gsk3) in immune cells is a major player 

INtlr4-mediated cytokine storm in patients with advanced cirrhosis. 

t. gustot (1), M. simon-rudler (2), M. fasseu (2), s. gandoura (2), W. abdel-razek (2), 

J. deviëre (1), d. lebrec (2), r. Moreau (2) / [1] UlB erasme, [2] inserM, Paris, france 

09.42 A06 the ras inhibitor farnesylthiosalicylic acid inhibits Egf and 

Igf2-induced cell growth in hepatocarcinoma cell lines. 

n. charette, c. de saeger, y. horsmans, i. leclercq, P. starkel / Ucl saint-luc 

09.54 A08 liver progenitor cell expansion in the injured mouse liver: 

do kupffer cells play a role? 

n. Van hul, n. lanthier, J. abarca-Quinones, M. Petit, y. horsmans, i. leclercq / Ucl saint-luc 

10.10 A09 2-log drop in viral load at one month: a new stopping rule in 

relapsers and non-responders Hcv patients re-treated with 

pegylated-IfN and ribavirin? 

P. deltenre (1), M. corouge (2), V. canva (2), M. el nady (2), a. louvet (2), h. castel (2), 

f. Wartel (2), s. dharancy (2), J. henrion (1), P. Mathurin (2) / [1] hôpital de Jolimont, 

haine-saint-Paul, [2] chU lille, france 

10.22 coffee breAk 


• 

room «LiJn» Basl / BlIc 

sEssION 2 

moDErators : M. adLEr, h. VaN VLIErBErGhE 

10.40 A10 management and outcome of biliary complications after liver transplantation. 

s. Van cleven, h. Peeters, d. de looze, M. de Vos, a. geerts, X. rogiers, r. troisi, 

B. de hemptinne, l. defreyne, P. Vanlangenhove, i. colle, h. Van Vlierberghe / Ugent 

10.52 A11 Hepatitis B virus (HBv) infection in Belgium: results of the Belgian 

association for the study of the liver (basl) registry of 1421 HBsag 

chronic carriers. 

P. deltenre (1), W. laleman (2), M. Van gossum (3), a. lenaerts (4), i. colle (5), M. adler (6), P. Michielsen (7), 

c. assene (8), J. delwaide (9), h. orlent (10), h. reynaert (11), f. d_heygere (12), P. langlet (13), 

g. robaeys (14), c. de galocsy (15), r. Brenard (16), d. sprengers (17), M.c. Mairlot (18), c. Preux (19), 

V. lefèbvre (20), J. henrion (1) / [1] hôpital de Jolimont, haine-saint-Paul, [2] kUleuven, [3] UlB saint-Pierre, 

Brussels, [4] chU charleroi, [5] UZ gent, [6] UlB erasme, [7] UZ antwerpen, [8] hôpitaux iris sud Molière, 

[9] Ulg sart tilman, [10] aZ sint-Jan, Brugge, [11] VUB UZ Brussels, [12] aZ groeninge, kortrijk, 

[13] UlB Brugmann, [14] Zol, genk, [15] hôpitaux iris sud Bracops, [16] hopital st Joseph, gilly, 

[17] aZ st-augustinus, Wilrick, [18] clinique saint-Jean, Brussels, [19] chU tivoli, la louvière, [20] chr, namur 

11.04 A12 Impact of current treatment practice and different scenarios improving 

screening, access to treatment and treatment efficacy on Hcvrelated 

mortality in Belgium: a mathematical modeling approach. 

P. deltenre (1), c. Moreno (2), P. Mathurin (3), M. adler (2), a. louvet (3), h. castel (3), 

f. Wartel (3), V. canva (3), J. henrion (1), i. lonjon-domanec (4), s. deuffic-Burban (5) / 

[1] hôpital de Jolimont, haine-saint-Paul, [2] UlB erasme, [3] chU lille, france, 

[4] Janssen-cilag, issy-les-Moulineaux, france, [5] inserM U795, lille, france 

11.16 A13 consequences of laparoscopy on liver ischemia during portal triad 

clamping in a swine model. 

n. gilson, B. nsadi, e. Pire, J.P. cheramy-Bien, J. Pincemail, e. cavalier, c. le goff, 

J.o. defraigne, M. Meurisse, o. detry / Ulg sart tilman 

11.28 A14 clinicopathological features of hepatocellular adenomas classified 

according to the bordeaux criteria. 

l. libbrecht (1), s. rogge (1), f. heindryckx (1), c. Verslype (2), W. Pauwels (3), r. troisi (1), 

a. geerts (1), i. colle (1), h. Van Vlierberghe (1) / [1] UZ gent, [2] kUleuven, [3] st lucas, ghent 

11.40 A15 liver transplantation for alcoholic liver disease: a retrospective analysis 

of recidivism, survival and risk factors predisposing to alcohol relapse. 

e. deruytter, c. Van steenkiste, a. geerts, h. Van Vlierberghe, B. de hemptinne, X. rogiers, 

r. troisi, f. Berrevoet, i. colle / UZ gent 

11.52 A16 Early transplantation improves survival of non-responders to corticosteroids 

in severe alcoholic hepatitis: a challenge to the 6 month rule of abstinence. 

c. Moreno (1), V. lucidi (1), n. Bourgeois (1), J. duclos-Vallée (2), J. dumortier (3), V. leroy (4), 

t. gustot (1), n. Boon (1), n. clumeck (1), P. deltenre (5), f. Pruvot (6), V. donckier (1), P. Mathurin (6) / 

[1] UlB erasme, [2] hôpital Paul Brousse, Villejuif, france, [3] hôpital edouard herriot, lyon, france, 

[4] chU grenoble, france, [5] hôpital de Jolimont, haine-saint-Paul, [6] chU lille, france 

12.04 2 Basl awards for the Best Basic and clinical Works presented. 

12.15 A17 : the Basl-BlIc spring meeting lecture: 

“apoptosis, from bench to bedside.” Prof. Marc Bilodeau (Montreal, canada). 


13 

Thursday 4

Thursday 4 

room «teun» 

• 

og-fWo 

“ gastroINtEstINal 

rEgulatory mEcHaNIsms” 

09.00 B01 : Pharmacology of inflammatory visceral pain. 

P. holzer / graz, austria 

09.45 B02 Quantification of brain activity evoked by colonic distention in rats 

using H215o micro PEt. 

M.M. Wouters (1), P. Vermaelen (1), s. Van Wanrooy (1), a. Van santvoort (1), 

o. Welting (2), a. nemethova (1), d. Vanderghinste (1), r.M. Van den wijngaard (2), 

k. Van laere (1), g.e. Boeckxstaens (1) / [1] kUleuven, [2] aMc amsterdam, netherlands 

10.00 B03 long-lasting visceral hypersensitivity following acute tNBs-colitis 

in rats. 

W. Vermeulen, J. de Man, t. Moreels, s. nullens, P. Pelckmans, B. de Winter / Uantwerp 

10.15 B04 Inducible nitric oxide synthase inhibition improves nitrergic 

dysfunction in diabetes-prone biobreeding rats. 

s. kindt, t. Vanuytsel, s. salim rasoel, W. Boesmans, g. de hertogh, P. Vanden Berghe, 

J. tack / kUleuven 


• 

sEssION 1 

moDErators : I. dEPOOrTErE, C. dELPOrTE 

sEssION 2 

moDErators : T. MOrEELs, J. TaCK 

11.00 B05 : Pharmacotherapy in somatic pain research 

g. hans / antwerp, Belgium 

11.30 B06 Intragastric pressure during intragastric nutrient drink infusion as a 

novel minimally invasive method to estimate meal-induced gastric 

accommodation. 

P. Janssen, J. tack / kUleuven 

11.45 B07 an increase in intra-gastric pressure is associated with a higher 

proximal extent of gastroesophageal reflux in healthy volunteers. 

k. Blondeau, V. Boecxstaens, r. farre, V. Mertens, a. Pauwels, g. Boeckxstaens, J. tack / 

kUleuven 

12.00 B08 Effect of azD3355, a novel gabab agonist, on reflux and lower 

esophageal sphincter function in patients with gErD with symptoms 

despite proton pump inhibitor treatment. 

g.e. Boeckxstaens (1), h. denison (2), M. ruth (2), J. adler (2), d.g. silberg (2), d. sifrim (3) / 

[1] kUleuven, [2] astraZeneca [3] Barts and the london school of Medicine and dentistry, U.k. 

12.15 B09 Bile acids in sputum of patients with cystic fibrosis. 

a. Pauwels (1), a. decraene (1), k. Blondeau (1), V. Mertens (1), r. farre (1), l. dupont (1), 

d. sifrim (2) / [1] kUleuven, [2] Barts and the london school of Medicine and dentistry, U. k. 

12.30 LuncH 


• 

room «teun» 

og-fWo 

“ gastroINtEstINal 

rEgulatory mEcHaNIsms” 

14.00 B10 : development of postinflammatory animal models 

and visceral hyperalgesia. 

n. Vergnolle / toulouse, france 

14.45 B11 Endogenous tachykinins modulate distension-induced peristalsis in 

the mouse colon mainly through activation of Nk1 and Nk2 but not 

Nk3 receptors. 

a. deiteren, B. de Winter, s. nullens, P. Pelckmans, J. de Man / Uantwerp 

15.00 B12 Prucalopride induces transient contraction and facilitates 

tachykininergic contractions in guinea pig proximal colon. 

f. de Vin (1), M. choi sze (1), J. de Maeyer (2), e. ghoos (2), J. schuurkes (2), 

r. lefebvre (1) / [1] heymans institute of Pharmacology, gent, [2] Movetis nV, turnhout 

15.15 B13 Expression and distribution of mas-related gene receptors mrgE and 

mrgf in the normal and inflamed murine ileum. 

l. avula (1), r. Buckinx (1), k. alpaerts (1), d. adriaensen (1), l. Van nassauw (2), 

J.P. timmermans (1) / [1] lab of cell Biology and histology, antwerp, 

[2] lab of cell Biology and histology/lab of human anatomy and embryology, antwerp 

15.30 B14 Presence of functional cgrp receptors on mouse bone 

marrow-derived mucosal mast cells. 

J. W. rychter (1), l. Van nassauw (2), J.P. timmermans (2), a. B kroese (1) / 

[1] UMcU & UU, Utrecht, netherlands, [2] Ua antwerp 


• 

sEssION 3 

moDErators : J.P. TIMMErMaNs, G. BOECKXsTaENs 

sEssION 4 

moDErators : JM. VaNdErWINdEN, r. LEFEBVrE 

16.15 B15 role of the gPr39 receptor, a member of the ghrelin receptor family, in the 

regulation of glucose homeostasis in a mouse model of diet-induced obesity. 

P.J. Verhulst, a. lintermans, s. Janssen, J. Buyse, J. tack, i. depoortere / kUleuven 

16.30 B16 role of ghrelin and ghrelin receptors in the effect of bitter taste 

receptor agonists on food intake and gastric emptying. 

s. Janssen, P.J. Verhulst, J. laermans, J. tack, i. depoortere / kUleuven 

16.45 B17 Ic cilium: immunofluorescence of (immotile) cilium in kit-ir interstitial 

cells of cajal. 

s. ralea, P. gromova, P. hagué, J.M. Vanderwinden / UlB 

17.00 B18 Bioengineering of circular oesophageal defects 

V. coulic (1), V. Maquet (2), P. delree (3), c. deprez (1), s. najar (1), s. Van daele (1) / 

[1] UlB Brugmann, Brussels, [2] kitoZyMe, herstal, [3] irsPg gosselies 

17.15 End of the program 


15 

Thursday 4

Thursday 4 

room «sAncY» 

• 

moDErators : P. dEPrEz, W. VaN sTEENBErGEN 

BElgIaN 

PaNcrEatIc cluB 

09.00 T01 : Pathophysiology of inflammatory pancreatic 

diseases and its clinical implications. 

J.l. frossard / geneva, switzerland 

09.30 T02 Impact of magnetic resonance cholangiopancreatography in the 

work-up of pancreatic diseases. 

J. rigaux (1), M. arvanitakis (1), M. Bali (1), M. costa Pereira (2), J. devière (1), 

M. delhaye (1), c. Matos (1) / [1] UlB erasme, [2] centro hospitalar de lisboa, Portugal 

09.45 T03 When Igg4 and ca19-9 yield conflicting results in a patient with 

pancreatic disease: lessons to be learned. 

W. Van steenbergen, f. claus, r. aerts, t. roskams / kUleuven 

10.00 T04 Intrapancreatic metastases: a surgical indication? 

g. roeyen, t. chapelle, W. Van riel, k. de greef, B. op de Beeck, J. somville, M. huizing, 

d. ysebaert / Ua antwerp 

10.15 T05 vascular reconstruction during pancreatoduodenectomy for ductal 

adenocarcinoma of the pancreas improves resectability but does not 

achieve patients cure. 

M. ouaissi, c. hubert, a. dili, d. glineur, P. astarci, r. Verhelst, c. sempoux, P. deprez, 

i. Borbath, l. annet, y. humblet, M. Van den eynde, P. scalliet, P. goffette, a. loundou, 

J.-f. gigot / Ucl saint luc 


11.00 T06 : screening individuals for pancreatic cancer: 

for whom? how? when? and how frequently? 

P. deprez / Ucl saint luc 

11.30 T07 Ectopic pancreatitis in the antrum, mimicking a submucosal 

gastric tumor. 

e. Vanhoutte, d. Vanbeckevoort, d. Bielen, k. op de Beeck, r. Vanslembrouck / kUleuven 

11.45 T08 coincidental finding of primary and metastatic tumours in a Whipple 

resection specimen. 

l. Verset, a. Mathieu, M. arvanitakis, J. closset, P. loi, M.a. Bali, M. delhaye, P. demetter / UlB erasme 

12.00 T09 septicaemic shock in a patient with chronic pancreatitis: report of an 

unusual case and its successful outcome by endoscopic treatment. 

W. Van steenbergen / kUleuven 

12.15 T10 Hemosuccus pancreaticus caused by rupture of a splenic artery 

aneurysm complicating chronic pancreatitis: an uncommon cause 

of gastrointestinal bleeding. 

n. hiltrop, J. hoste, g. lambrecht, a. Janssen, M. cool, g. deboever / aZ damiaan, oostende 

12.30 T11 Incidental finding of a pancreatic cystic lesion during the postoperative 

follow-up of a right nephrectomy for renal cell carcinoma. 

M. delhaye, M. arvanitakis, M.a. Bali, c. Matos, P. demetter, J. devière, J. closset / UlB erasme 



oom «fLorentine» small BoWEl grouP 

• 

14.00 V01 Perspectives for the 2 nd generation of colon capsule. 

a. Van gossum / UlB erasme 

14.15 V02 spiral enteroscopy versus balloon enteroscopy. 

i. demedts / kUleuven 

14.30 V03 obscure gastroIntestinal Bleeding (ogIB): algorithm and discussion. 

a. Van gossum / UlB erasme and experts from the small Bowel group 

• 

moDErators : d. dE LOOzE, d. urBaIN 

moDErators : C. rEENaErs, E. MaCKEN 

15.00 V04 atypical and rare indications of small bowel capsule. 

d. Urbain / UZ Brussel 

15.15 V05 capsule endoscopy for obscure gastrointestinal bleeding in liège: 

results and long-term outcome of the patients. 

s. Bessemans, e. louis, J. Belaiche, c. reenaers / Ulg sart tilman 

15.25 V06 single-balloon enteroscopy: multicentric experience in Belgium. 

t. Moreels (1), d. Urbain (2) / [1] UZ antwerpen, [2] UZ Brussel 

15.45 V07 Impact of reimbursement policy in Belgium on the referral pattern 

and diagnostic yield of capsule endoscopy. 

s. de rouck, d. de looze / UZ gent 



17 

Thursday 4

Thursday 4 

room «LiJn» JoINt mEEtINg 

• 

sEssION a : shOrT COMMuNICaTIONs 

moDErators : J. dELWaIdE, J. LEruT 

14.00 D01 Impact of tight glycemic control in patients with decompensated 

chronic liver disease admitted to intensive care: results of a 

single-centre randomized controlled trial. 

W. laleman, a. Moonen, c. Verslype, P. Meersseman, f. nevens, g. Van den berghe, 

a. Wilmer / kUleuven 

14.10 D02 liver histology according to the presence of the metabolic syndrome 

in overweight and obese patients. 

a. Verrijken, s. francque, i. Mertens, g. hubens, e. Van Marck, P. Michielsen, l. Van gaal / 

UZ antwerpen 

14.20 D03 NaflD liver fat score strongly correlates with histological severity of 

NaflD and NasH in a large cohort of prospectively included overweight 

patients. 

s. francque, a. Verrijken, i. Mertens, g. hubens, e. Van Marck, P. Michielsen, l. Van gaal / 

UZ antwerpen 

14.30 D04 liver transplantation using grafts from donors older than seventy 

and eighty years old. 

t. darius, d. Monbaliu, W. coosemans, r. aerts, i. Jochmans, J. de roey, B. desschans, 

g. Van helleputte, d. claes, W. laleman, W. Van steenbergen, c. Verslype, f. nevens, 

J. Pirenne / kUleuven 

14.40 D05 urgent early (≤ 15 days) arterial revascularization following hepatic 

artery thrombosis may avoid graft loss and improve outcome in adult 

liver transplantations. 

a. scarinci, M. sainz-Barriga, i. colle, h. Van Vlierberghe, a. geerts, B. Van den Bossche, 

f. Berrevoet, X. rogiers, r. troisi, B. de hemptinne / UZ gent 

14.50 D06 outcome of patients with hepatocellular carcinoma listed for liver 

transplantation before and after the mElD allocation system. 

B. Vos, c. Moreno, V. lucidi, a. gerkens, a. Buggenhout, n. Bourgeois, V. donckier, 

M. adler / UlB erasme 

15.00 D07 : marc Hautekeete lecture: «sepsis and cirrhosis» 

J.l. Vincent / UlB erasme 



• 

room «LiJn» JoINt mEEtINg 

sEssION B : shOrT COMMuNICaTIONs 

moDErators : M. dELhayE, h. rEyNaErT 

16.00 D08 Evaluation of pancreatic tumors with contrast enhanced-endoscopic 

ultrasonography and Eus-strain ratio elastography. 

a. Badaoui (1), i. Borbath (2), M. Maffei (2), t. aouattah (2), c. gillain (3), t. de ronde (1), 

P. deprez (2) / [1] Ucl Mont-godinne, [2] Ucl saint-luc, [3] hopital st Joseph, gilly 

16.10 D09 Endoscopic ultrasound (Eus) guided transluminal drainage of 

pancreatic duct obstruction: long term outcome. 

M. ergun, t. aouattah, c. gillain, h. Piessevaux, J.f. gigot, c. hubert, P. deprez / 

Ucl saint-luc 

16.20 D10 comparison of sporadic genetically determined pancreatitis with an 

aged matched control group of patients with idiopathic pancreatitis. 

c. hamoir, X. Pepermans, k. dahan, h. Piessevaux, a. geubel, J.f. gigot, P. deprez / 

Ucl saint-luc 

16.30 D11 Hepatocellular carcinoma and underlying liver cirrhosis; influence on 

treatment or a prognostic value? 

c.d. Witjes, r.a. de Man, f.a. eskens, r.s. dwarkasing, P.e. Zondervan, c. Verhoef, 

J.n. ijzermans / erasmus Medical center, rotterdam, netherlands 

16.40 D12 Is a more agressive surgical management of klatskin tumour granted 

by better patients : mortality and survival rates? 

J.f. gigot, c. hubert, B. radu, c. sempoux, P. deprez, l. annet, P. scalliet, P. goffette / 

Ucl saint-luc 

16.50 D13 gene expression profiling of circulating pancreatic tumor cells 

obtained by a negative depletion strategy. 

g. sergeant, r. Van eijsden, t. roskams, V. Van duppen, J. Van Pelt, B. topal / kUleuven 

17.00 D14 long-term results of adult and paediatric patients operated from 

congenital bile duct cysts: a multi-institutional study of 98 patients. 

c. hubert (1), J.y. Mabrut (2), J. Baulieux (2), c. ducerf (2), e. de la roche (2), 

c. Partensky (3), o. Boillot (3), M. audet (3), r. dubois (3), J.P. chappuis (3), c. gouillat (4), 

J. lerut (1), r. reding (1), J.B. otte (1), J. de Ville de goyet (1), P.J. kestens (1), 

J.f. gigot (1) / [1] Ucl saint-luc, [2] la croix-rousse hospital, lyon, france, 

[3] hôpital edouard herriot, lyon, france, [4] hôtel dieu hospital, lyon, france 

17.10 D15 management of malignant biliary obstruction by endoscopic 

ultrasonography-guided drainage. 

a. Badaoui (1), c. gillain (2), t. aouattah (3), i. Borbath (3), t. de ronde (1), P. deprez (3) / 

[1] Ucl, Mont-godinne, [2] hopital st Joseph, gilly, [3] Ucl saint-luc 

17.20 D16 Bacterial DNa is rarely detected in the serum and the ascitic fluid of noninfected 

outpatients with cirrhosis and ascites treated by paracentesis. 

t. serste (1), f. Bert (2), V. leflon (2), c. chauveau (2), t. asselah (2), c. francoz (2), f. durand (2), 

d. Valla (2), r. Moreau (2), M. nicolas-chanoine (2) / [1] UlB saint-Pierre, [2] hôpital Beaujon, 

clichy, france 

17.30 End of the session 


19 

Thursday 4

Thursday 4 

room «sAncY» IBD 

• 

14.00 I01 : «Er stress and autophagy». 

a. kaser / innsbruck, austria 

14.25 I02 Haptoglobin polymorphisms are associated with ulcerative colitis 

and crohn’s disease. 

l. Márquez, i. cleynen, k. Machiels, s. organe, M. ferrante, l. henkaerts, V. Ballet, 

P. rutgeerts, s. Vermeire / kUleuven 

14.35 I03 oxigen sensor inhibition attenuates tNf-α induced intestinal epithelial 

damage by hypoxia inducible factor (HIf) 1-dependent repression of 

fas-associated death domain protein (faDD). 

P. hindryckx, M. de Vos, P. Jacques, l. ferdinande, h. Peeters, k. olivier, B. Brinkman, 

P. Vandenabeele, d. laukens / UZ gent 

14.45 I04 small animal PEt-ct as a non-invasive method to evaluate terminal 

ileal inflammation in a murine model of crohn’s disease. 

P. hindryckx, s. staelens, s. deleye, h. Peeters, d. laukens, M. de Vos / UZ gent 

14.55 I05 Evolution and predictive factors of relapse in uc patients treated with 

5-asa after a first course of systemic steroids. 

c. Bello, e. louis, J. Belaiche, c. reenaers / Ulg 

15.05 I06 : «Impaired autophagy in crohn’s disease: an opened 

15.30 

gate to invasive bacteria?». 

a. darfeuille-Michaud / clermont-ferrand, france 

coffee breAk 

• 

moDErators : s. VErMEIrE, E. LOuIs 

moDErators : d. FraNChIMONT, T. MOrEELs 

16.00 I07 : «crohn’s disease: th17 and/or th1 disease?» 

16.25 I08 

s. Brand / Munich, germany 

fatigue in active and quiescent inflammatory bowel disease: 

a study investigating its impact on quality of life and possible 

underlying mechanisms. 

h. Peeters, c. de roo, a. Malfait, d. laukens, M. de Vos / UZ gent 

16.35 I09 Impact of an extensive thiopurine methyltransferase (tPmt) 

genotyping in inflammatory bowel disease patients who experienced 

myelosuppression during antipurine therapy. 

o. dewit (1), t. Moreels (2), f. Baert (3), h. Peeters (4), c. reenaers (5), M. de Vos (4), 

P. Van hootegem (6), V. Muls (7), g. Veereman (8), f. Mana (9), J. holvoet (10), 

s. naegels (10), M. Van outryve (2), y. horsmans (1), J.l. gala (1) / [1] Ucl saint-luc, 

[2] UZ antwerpen, [3] hart hospital roeselare-Menen, [4] UZ gent, [5] Ulg 

[6] aZ sint-lucas, Brugge, [7] UlB saint-Pierre, [8] Queen Paola children’s hospital, 

antwerpen, [9] VUB UZ Brussel, [10] Zna Middelheim, antwerpen 


oom «sAncY» IBD 

16.45 I10 High Infliximab through levels are associated with mucosal healing in 

crohn’s disease. 

W. Van Moerkercke, c. ackaert, g. compernolle, M. Jürgens, i. cleynen, g. Van assche, 

P. rutgeerts, a. gils, s. Vermeire / kUleuven 

16.45 I11 lack of crP response in patients with active crohn’s disease is characterized 

by low Il-6 concentrations but not with genetic variants in the crP gene. 

M. Jürgens (1), i. cleynen (1), s. organe (1), f. schnitzler (2), V. Ballet (1), M. noman (1), 

g. Van assche (1), P. rutgeerts (1), s. Vermeire (1) / [1] kUleuven [2] University hospital 

grosshadern, Munich, germany 

17.05 I12 

d. elewaut / gent 

: «tNfdeltaarE mice: a model to study EIms in cD». 


• 

room «tiffAnY» 

BElgIaN HP 

stuDy grouP 

14.00 H01 the diagnosis of resistance of H. Pylori by other methods than 

culture: what, how, costs and availability 

V.y. Miendje deyi / UlB Brugmann 

14.25 H02 rescue therapy for H. Pylori 

a. Burette / chirec Brussels 


• 

moDErator : P. BONTEMs 

moDErator : V. LaMy 

15.05 H03 Non conventional therapies for H. Pylori 

r. ntounda / UlB saint-Pierre 

15.30 H04 some negative aspects of PPI 

V. Mattens, f. Mana, d. Urbain / UZ Brussel 



21 

Thursday 4

Thursday 4 

FrIday 5 

13H00 -14H00 

• 

bAsL / bLic 

Poster session 

rEaDErs for a guIDED tour: J. dELWaIdE, a. GEErTs 

A18 a 7 gene set associated with chronic hypoxia of universal prognostic 

importance in hepatocellular carcinoma. 

h. Van Malenstein (1), o. gevaert (1), l. libbrecht (2), a. daemen (1), J. allemeersch (1), 

f. nevens (1), e. Van cutsem (1), d. cassiman (1), B. de Moor (1), c. Verslype (1), J. Van Pelt (1) / 

[1] kUleuven, [2] UZ gent 

A19 the impact of elevation of total bilirubin level on serum 

n-glycosylation patterns in mice and men. 

B. Blomme (1), c. Van steenkiste (1), J. Van huysse (2), i. colle (1), n. callewaert (1), 

h. Van Vlierberghe (1) / [1] UZ gent, [2] aZ sint-Jan, Brugge, 

A20 N-glycosylation patterns of serum proteins to make the distinction 

between steatosis of the liver and non-alcoholic steatohepatitis in 

obese patients scheduled for bariatric surgery. 

B. Blomme, l. libbrecht, P. Pattyn, y. Van nieuwenhove, d. Van de Putte, a. geerts, i. colle, 

n. callewaert, h. Van Vlierberghe / UZ gent 

A21 N-glycosylation of immunoglobulin g and its role in the alteration 

of total serum protein N-glycome in two mouse models of chronic 

liver disease. 

B. Blomme, n. callewaert, h. Van Vlierberghe / UZ gent 

A22 moderate and excessive alcohol intake impact transplant-free survival: 

a longitudinal study in Hcv cirrhotic patients. 

P. deltenre (1), M. el nady (2), M. corouge (2), V. canva (2), a. louvet (2), h. castel (2), f. Wartel (2), 

s. dharancy (2), J. henrion (1), P. Mathurin (2) / [1] hôpital de Jolimont, haine-saint-Paul, 

[2] chU lille, france 

A23 occurrence and clinicopathological relevance of prognostic markers 

(k19, EPcam, and afP) in hepatocellular carcinoma. 

o. govaere (1), a. katoonizadeh (1), B. spee (1), f. de luca (2), c. Janssen (1), s. Vander Borght (1), 

J. Verheij (3), c. Verslype (1), r. aerts (1), B. topal (1), J. Pirenne (1), f. nevens (1), V. desmet (1), 

M. Pinzani (2), t. roskams (1) / [1] kUleuven, [2] University, firenze, italy, 

[3] erasmus Medical center, rotterdam, netherlands, 

A24 the fibro7-score: a novel serum proteome-and clinical biochemistrybased 

predictive model for chronic hepatitis c liver fibrosis. 

k.J. cheung, k. tilleman, d. deforce, i. colle, h. Van Vlierberghe / UZ gent 

A25 Donation after cardiac death liver transplantation: is donor 

age an issue? 

o. detry, a. deroover, J.P. squifflet, M.f. hans, B. lambermont, s. lauwick, M. Meurisse, J. delwaide, 

P. honoré / Ulg 

A26 Hepatitis B-delta virus co-infection in Belgium: joint analysis of 

prospective data of the Basl HDv and HBv registries. 

e. ho (1), P. deltenre (2), M. nkuize (3), J. delwaide (4), J. henrion (2), r. Brenard (5), c. de galocsy (6), 

i. colle (7), f. d heyghere (8), h. orlent (9), P. langlet (10), W. laleman (11), P. Michielsen (1) / 

[1] Ua antwerp, [2] hôpital de Jolimont, haine-saint-Paul, [3] UlB saint-Pierre, [4] Ulg, 

[5] hopital st Joseph, gilly, [6] ch J. Bracops, Brussels, [7] UZ ghent, [8] aZ groeninge, kortrijk, 

[9] aZ sint-Jan, Brugge, [10] UlB Brugmann, [11] kUleuven 


A27 Plasma soluble st2 receptor is increased in human alcoholic liver 

disease and correlates with the prognostic index in alcoholic 

hepatitis. 

a. lemmers, c. Moreno, r. ouziel, d. degré, e. trepo, e. Quertinmont, V. Vercruysse, 

o. le Moine, J. devière, t. gustot / UlB erasme 

A28 circulating antibodies to commensal bacillus subtilis flagellin as a new 

biomarker for bacterial translocation-driven increased microbe-host 

interactions in patients with cirrhosis. 

t. gustot (1), a. lemmers (1), c. Moreno (1), d. degré (1), r. ouziel (1), d. franchimont (1), 

d. lebrec (2), r. Moreau (2), J. devière (1) / [1] UlB erasme, [2] inserM Bichat-Beaujon, Paris, france 

A29 vascular hyporeactivity in partial portal vein ligation-induced 

portal hypertension is mediated by a specific 

cyclooxygenase 2-related mechanism. 

s. francque, W. Verlinden, i. Brosius, B. de Winter, a. herman, P.Pelckmans, P. Michielsen / 

Ua antwerpen 

A30 vascular hyporeactivity in steatosis-induced portal hypertension is 

mediated by a specific cyclooxygenase 2-related mechanism. 

s. francque, W. Verlinden, i. Brosius, B. de Winter, a. herman, P. Pelckmans, P. Michielsen / 

Ua antwerpen 

A31 the vasopressin-2-receptor antagonist satavaptan improves portal 

hypertension in the non-ascitic thioacetamide cirrhotic rat within a 

narrow safe and effective dose-range. 

W. laleman (1), J. trebicka (2), l. Van landeghem (1), i. Vander elst (1), t. sauerbruch (2), 

d. cassiman (1), f. nevens (1) / [1] kUleuven, [2] University hospital, Bonn, germany 

A32 combination therapy with β-carotene and vitamin c significantly ameliorated 

biochemical and histological signs in liver damage caused by ccl4 i 

ntoxication in rats. 

s. Wamutu (1), s. francque (2), s. chatterjee (2), e. Musisi (1), g.W. Muyombya (1), J. Weyler (2), 

e. Van Marck (2), g.s. Bimenya (1), P. Michielsen (2) / [1] Makarere University, kampala, Uganda, 

[2] Ua, antwerpen 

A33 Differential gene expression profile in porcine livers subjected to warm 

ischemia. 

e. Balligand (1), J. Van Pelt (1), Q. liu (1), h. Van Malenstein (1), d. Monbaliu (1), V. heedfeld (1), 

t. Wylin (1), t. ayoubi (3), W. Van delm (1), P. Van hummelen (2), J. Pirenne (1), k. Vekemans (1) / 

[1] kUleuven, [2] rutgers University, new Jersey, Usa 

A34 aldehyde dehydrogenase activity: a new strategy to purify liver 

progenitor cells. 

l. dollé, J. Mei, J. Best, c. empsen, h. reynaert, a. geerts, l. Van grunsven / VUB 

A35 Effects of large pore hemofiltration in a swine model of fulminant 

hepatic failure. 

o. detry, n. Janssen, e. cavalier, P. delanaye, J.P. cheramy-Bien, P. honoré, J.o. defraigne, 

B. lambermont / Ulg 

A36 the evolution of laparoscopic left lateral sectionectomy without 

pringle maneuver: through resection of benign and malignant tumors 

to living liver donation. 

B. Van den Bossche, f. Berrevoet, M. sainz-Barriga, B. de hemptinne, r. troisi / UZ gent 


23 

Thursday 4

2010 XXII nd BElgIaN WEEk of gastroENtErology 

tHursDay, 4 

frIDay, 5 

s a t u r D a y , 

6 

rooms lIJN tEuN 

Morning 

lUnch 

13h15-14h00 

afternoon 

17h30-18h15 

18h15-19h00 

Morning 

lUnch 

13h15-14h00 

afternoon 

17h30-18h15 

18h15-19h00 

Morning 

lUnch 

afternoon 

bAsL / bLic 

Joint 

meeting 

HIltoN 

3rD floor 

"eXHibition AreA" 

Belle ePoQUe rooM 

Joint meeting 

«eXHibition AreA» 


sAteLLite sYmPosium 

soLvAY 

Joint meeting 


scHering PLougH 


menArini 

og - fwo 

og - fwo 


movetis 


giLeAd 

sYmPosium of tHe 7 societies 




bAYer 

sYmPosium of tHe 7 societies 


coNfErENcE cENtEr 

beLgiAn 

PAncreAtic cLub 

ibd 

reseArcH grouP 

bgdo / 

rAdioLogY 

bgdo / 

PAtHoLogY 

2ND floor 1st floor 

saNcy tIffaNy florENtINE cullINaN III 

gi PAtHoLogY cLub 

tHe President’s dAY 



gi PAtHoLogY cLub 

tHe President’s dAY 

HP 

reseArcH grouP 

bsgie / 

besPgHAn 

smALL boweL 

grouP 

bgdo / 

rAdioLogY 

bgdo / 

PAtHoLogY 

gA srbge 

nutrition 

grouP 

LA / cs 

srbge 

ActA 

gAstroenteroLogicA 

beLgicA 


25 


FrIday 5 

room «teun/LiJn» JoINt mEEtINg 

• 

sEssION C : shOrT COMMuNICaTIONs 

moDErators : Karen GEBOEs, J.L. VaN LaEThEM 

08.30 D17 the “liver first strategy” in stage Iv colorectal cancer disease: the 

ghent university hospital experience. 

s. laurent (1), k. geboes (1), o. Varin (1), B. Van den Bossche (1), a. scarinci (1), f. Berrevoet (1), 

X. rogiers (1), P. Pattyn (1), W. ceelen (1), y. Van nieuwenhove (1), B. de hemptinne (1), 

M. Peeters (2), l. libbrecht (1), r. troisi (1) / [1] UZ gent, [2] UZ antwerpen 

08.40 D18 Phase II study of helical tomotherapy for oligometastatic colorectal cancer. 

M. de ridder, B. engels, a. sermeus, h. everaert, B. neyns, h. Vermessen, d. Verellen, 

d. Urbain, g. storme / UZ VUB Brussel 

08.50 D19 anastomotic complications following Ivor lewis esophagectomy in 

patients treated with neoadjuvant chemoradiation are related to 

radiation dose to the gastric fundus. 

W. ceelen, c. Vande Walle, t. Boterberg, k. geboes, s. laurent, d. Vande Putte, 

y. Van nieuwenhove, o. Varin, P. Pattyn / UZ gent 

09.00 D20 resection of liver metastases after neo-adjuvant treatment with 

bevacizumab : the ghent university hospital experience. 

k. geboes (1), B. Van den Bossche (1), s. laurent (1), M. craninx (2), B. claerhout (3), 

M. hanssens (4), B. Berghmans (4), B. Van overberghe (4), l. Verstraete (4), o. Varin (5), 

f. Berrevoet (1), X. rogiers (1), B. de hemptinne (1), c. cuvelier (1), h. Monirath (1), 

l. libbrecht (1), M. Peeters (5), r. troisi (1) / [1] Ugent, [2] aZ heilige amilie, reet, 

[3] aZ alma, eeklo, [4] aZ sint-elisabeth, Zottegem, [5] UZ antwerp 

09.10 D21 spect imaging of apoptotic tumor response in a colorectal tumor model. 

c. Vangestel (1), n. Van damme (1), g. Mees (2), s. staelens (3), c. Van de Wiele (3), 

M. Peeters (4) / [1] UZ gent, [2] UMc, groningen, netherlands, [3] U gent, [4] UZ antwerpen 

09.20 D22 Indoleamine 2,3-dioxygenase expression in the tumour invasion front 

is an independent prognostic factor in Pt1-4N1mX staged colorectal 

cancer. 

l. ferdinande (1), a. Mathieu (2), c. decaestecker (2), t. Van Maerken (1), a.M. negulescu (2), 

X. Moles lopez (2), c. cuvelier (1), i. salmon (2), P. demetter (2) / [1] UZ gent, [2] UlB erasme 

09.30 D23 Endorectal ultrasound and magnetic resonance imaging in staging of 

rectal cancer in routine daily practice. 

e. cesmeli (1), k. geboes (1), P.J. de Munck (1), W. ceelen (1), B. claerhout (1), 

J. Van ongeval (2), a. de Backer (2), P. smeets (1), P. Pattyn (1), M. Peeters (3), M. de Vos (1) / 

[1] UZ gent, [2] st lucas, gent, [3] UZ antwerpen 

09.40 D24 lat-1 expression and 4-fmP pet imaging in colorectal cancer. 

M. de ridder, B. engels, a. sermeus, h. everaert, B. neyns, h. Vermessen, d. Verellen, d. Urbain, 

g. storme / VUB UZ Brussel 

09.50 D25 Prognostic significance of N stage, nodal harvest, and lymph node 

ratio in locally advanced esophageal cancer patients treated with 

neoadjuvant chemoradiation. 

W. ceelen, c. staelens, l. Maes, V. ochieng, l. libbrecht, t. Boterberg, o. Varin, d. Vande Putte, 

y. Van nieuwenhove, P. Pattyn / UZ gent 


• 


PLENary sEssION d : BEsT COMMuNICaTIONs 

moDErators : h. LOuIs, d. dE LOOzE 

10.30 D26 radiofrequency ablation in Barrett’s esophagus: first Belgian safety 

and efficacy data. 

r. Bisschops (1), t. lerut (1), h. Willekens (1), r. Pouw (2), g. de hertogh (1), J. Bergman (2), 

P. nafteux (1), P. rutgeerts (1), g. coremans (1) / [1] kUleuven, [2] aMc, amsterdam, netherlands 

10.45 D27 otilonium bromide improves frequency of abdominal pain, severity 

of distention. 

J. tack / kUleuven 

11.00 D28 Efficacy and tolerability of the novel reflux inhibitor, azD3355, as 

add-on treatment in patients with gErD with continued symptoms 

despite proton pump inhibitor therapy. 

g. Boeckxstaens (1), h. Beaumont (2), J.g. hatlebakk (3), d.g. silberg (4), J. adler (4), 

h. denison (4) / [1] kUleuven, [2] academic Medical center, amsterdam, netherlands, [3] 

haukeland University hospital, Bergen, norway, [4] astraZeneca 

11.15 D29 symptom severity and quality of life in patients with chronic 

constipation: pooled results from three identical randomised 

placebo-controlled trials with prucalopride. 

d. dubois (1), r. kerstens (2), l. Vandeplassche (2), J. tack (3) / 

[1] Patient Value solutions, huldenberg, [2] Movetis, [3] kUleuven 

11.30 D30 EsD in Barrett’s esophagus high grade dysplasia and mucosal cancer: 

prospective comparison with caP-Emr. 

P. deprez, h. Piessevaux, t. aouattah, c.P. yeung, c. sempoux, a. Jouret-Mourin / Ucl saint-luc 

11.45 D31 the european achalasia trial: a randomized multi-centre trial 

comparing endoscopic pneumodilation and laparoscopic heller 

myotomy as primary treatment. 

g.e. Boeckxstaens (1), V. annese (2), s. Bruley des Varannes (3), s. chaussade (4), M. costantini (5), 

i. elizalde (6), U. fumagalli (7), M. gaudric (4), e. Metman (8), J. Pérez de la serna (9), W.o. rohof (10), 

a.J. smout (11), J. tack (12), g. Zaninotto (13), o.r. Busch (10) / [1] kUleuven, [2] ospedale cssirccs, 

san giovanni rotondo, italy, [3] human nutrition research center, nantes, france, [4] inserM, 

Paris, france, [5] University of Padua, italy, [6] hospital Barcelona, spain, [7] istituto clinico humanitas, 

Milan, italy, [8] hôpital saint antoine, Paris, france, [9] hospital Universitario, Madrid, spain, [10] aMc 

amsterdam, netherlands, [11] UMc, Utrecht, netherlands, [12] kUleuven, [13] University Padova, italy 

12.00 D32 report (glEm-lok) on current Barrett’s esophagus management in 

Belgium : comments and recommendations. 

r. Bisschops (kUl), P. deprez (Ucl), J-c. debongnie (ottignies), c. de galoscy (Bracops), 

a. elewaut (UZg), r. fiasse (Ucl) 

12.15 D33 Belgian guidelines for the management of upper gI bleeding. 

i. colle, J. deflandre, J. delwaide, e. d’hondt, Pf. laterre, o. lemoine, e. Macken, a. Penaloza, 

a. Wilmer for the Upper gi bleeding Work group in name of the Basl, BesediM, Bsgie, siZ, 

srBge and VVge 

12.30 Professional gastroenterology association 

12.45 End of morning session 


27 

FrIday 5

FrIday 5 


• 

PLENary sEssION E : BEsT COMMuNICaTIONs 

moDErators : M. hIELE; h. PIEssEVauX 

14.00 D34 Early metabolic response evaluation with 18-fDg PEt-ct in ct3-4N+ 

cancer of the oesophagus and gE-junction treated with induction 

chemoradiotherapy is not a useful tool to predict histopathological 

response and outcome. 

g. sergeant, c. deroose, g. de hertogh, J. Moons, W. coosemans, h. decaluwé, g. decker, 

P. de leyn, P. nafteux, d. Van raemdonck, l. Mortelmans, a. lerut / kUleuven 

14.15 D35 molecular reclassification of crohn’s disease by cluster analysis of 

genetic variants. 

i. cleynen (1), J. Mahachie John (2), l. henckaerts (1), W. Van Moerkercke (1), 

P. rutgeerts (1), k. Van steen (3), s. Vermeire (1) / [1] kUleuven, [2] Ugent, [3] Ulg 

14.30 D36 telaprevir (tvr) Q8H or Q12H combined with either peginterferon 

(PEg-IfN, P) alfa-2a or alfa-2b and ribavirin (rBv, r) in 

treatment-naïve genotype 1 hepatitis c : final results of the 

randomized, open-label, multicenter phase 2 study c208. 

f. nevens (1), y. horsmans (2), h. Van Vlierberghe (3), J. delwaide (4), M. adler (5), 

P. Marcellin (6), e. de Paepe (7), s. de Meyer (7), M. Beumont-Mauviel (7) / 

[1] kUleuven, [2] Ucl saint-luc, [3] Ugent, [4] Ulg, [5] UlB erasme, 

[6] hôpital Beaujon, clichy, france, [7] tibotec bvba 

14.35 D37 colorectal EsD may avoid surgery in early neoplasms. 

M. Maffei, h. Piessevaux / Ucl saint-luc 

15.00 D38 chemotherapy induction followed by preoperative chemoradiation 

versus preoperative chemoradiation alone in locally advanced rectal 

adenocarcinoma: a randomized controlled phase II study. 

r. Maréchal (1), B. Vos (1), M. Polus (2), t. delaunoit (3), M. Peeters (4), P. demeeter (1), 

P. coucke (2), B. frederick (5), a. hendlisz (6), a. demols (1), P. Van houtte (6), J. Van de stadt (1), 

J.l. Van laethem (1) / [1] UlB erasme, [2] Ulg, [3] hôpital de Jolimont, [4] UZ gent, [5] rhMs, 

Baudour, [6] institut Jules Bordet 

15.15 D39 malignant tumours and patterns of mortality in 200 patients with 

primary sclerosering cholangitis (4 to 29 yr follow up). 

J. fevery, l. henckaerts, s. Vermeire, P. rutgeerts, f. nevens, W. Van steenbergen / kUleuven 

15.30 D40 assessment and prognostic value of regression after neoadjuvant therapy 

in rectal cancer: the role of tumor shrinkage and fragmentation. 

M. hav, c. cuvelier, k. geboes, s. laurent, n. Van damme, t. Boterberg, W. ceelen, P. Pattyn, 

l. libbrecht / UZ gent 

15.45 D41 Belgian multicenter experience with the biodegradable ella-stent in 

benign strictures of the digestive tract. under the auspices of the BsgIE. 

M. ibrahim (1), a. Vandermeeren (2), V. Van Maele (3), P.h. deprez (4), i. ruytjens (5), 

t. Moreels (6), e. Macken (6), J. Verhofstadt (7), P. Vergauwe (8), d. de looze (9), o. le Moine (1) 

/ [1] UlB erasme [2] chirec-cavell, Brussels, [3] aZ st.lucas, gent, [4] Ucl saint-luc, 

[5] Zna Middelheim, antwerpen, [6] UZ antwerpen, [7] Ziekenhuis dendermonde, 

[8] aZ groeninge, kortrijk, [9] UZ gent 


oom «teun/LiJn» JoINt mEEtINg 


• 

sEssION F : shOrT COMMuNICaTIONs 

moDErators : s. VErMEIrE, T. MOrEELs 

16.20 D42 outcome of non variceal upper gastrointestinal bleeding 

in Belgium. 

h. Piessevaux, c. taeter / Ucl saint-luc 

Healthcare resource consumption for non-variceal upper 

gastrointestinal bleeding in Belgium 

h. Piessevaux, c. taeter / Ucl saint-luc 

16.40 D43 Intestinal mucosal gene expression of endothelial cell adhesion 

molecules in patients with inflammatory bowel disease before 

and after first infliximab treatment. 

i. arijs (1), r. Quintens (1), k. lemaire (1), l. Van lommel (1), k. Van steen (2), 

g. de hertogh (1), g. Van assche (1), s. Vermeire (1), k. geboes (1), f. schuit (1), 

P. rutgeerts (1) / [1] kUleuven, [2] Ulg 

16.50 D44 screening colonoscopy: conventional imaging versus pancolonic 

indigo carmine dye. 

s. Mouzyka, a. Vinnytska / hospital lissod, kiev, Ukraine 

17.00 D45 Diagnostic (dis)agreement between conventional manometry criteria 

and the chicago classification of esophageal motility disorders in 

tertiary care patients. 

s. kindt, n. rommel, J. tack / kUleuven 

17.10 D46 subclinical intestinal dysbiosis in unaffected first-degree relatives of 

crohn’s disease patients. 

M. Joossens (1), g. huys (2), V. de Preter (1), P. rutgeerts (1), P. Vandamme (2), 

s. Vermeire (1) / [1] kUleuven, [2] U gent 

17.20 D47 comparison of complication rates of push-type and pull-type 

percutaneous endoscopic gastrostomy (peg) in oncology patients. 

e. Van dyck, t. Moreels, e. Macken, B. roth, P. Pelckmans / UZ antwerpen 

17.30 D48 Efficacy and safety profile of certolizumab pegol : results from the 

compas programme in Belgium. 

s. Vermeire (1), k. Vandenbroek (1), M. noman (1), f. Van de Mierop (2), f. Mana (3), 

f. Baert (4), e. louis (5), P. caenepeel (6), e. humblet (6), c. claessens (7), g. dhaens (8), 

t. Moreels (9), h. Peeters (10), P. Potvin (11), P. Potvin (12), g. Van assche (1), P. rutgeerts (1), 

d. franchimont (13) / [1] kUleuven, [2] sint augustinus Ziekenhuis, antwerpen, 

[3] UZ VUB Brussel, [4] hart hospital roeselare-Menen, [5] Ulg, [6] Zol, genk, Belgium, 

[7] aZ sint-Jozef, turnhout [8] imelda gi clinical research centre, Bonheiden, 

[9] UZ antwerpen, [10] UZ gent, [11] Zna Middelheim, antwerpen, 

[12] st Jozefkliniek, Bornem, [13] UlB erasme 


29 

FrIday 5

FrIday 5 

room 

«sAncY/fLorentine» 

• 

BgDo 

raDIology / 

PatHology cluB 

09.00 P01 Prospective randomized study comparing hepatic intra-arterial injection 

of yttrium90 resin-microspheres (HaI-y90) with protracted Iv 5fu 

(5fu cI) versus 5fu cI alone for patients with liver-limited metastatic 

colorectal cancer (lmcrc) refractory to standard chemotherapy (ct). 

a. hendlisz (1), M. Van den eynde (2), M. Peeters (3), l. defreyne (3), g. Maleux (4), 

J. Vannoote (4), P. delatte (1), M. Paesmans (1), J.l. Van laethem (5), P. flamen (1) / 

[1] UlB Bordet, [2] Ucl saint-luc, [3] UZ gent, [4] kUleuven, [5] UlB erasme 

09.10 P02 Eus predicts local resection for rectal cancer. 

e cesmeli, k. geboes, P.J. de Munck, B. claerhout, W. ceelen, P. Pattyn, d. de looze, 

M. Peeters, M. de Vos / UZ gent 

09.20 P03 laparoscopic resection of colorectal liver metastases: a single center case 

control matched-pairs analysis. 

B. Van den Bossche, a. scarinci, f. Berrevoet, X. rogiers, l. libbrecht, B. de hemptinne, 

r. troisi / UZ gent 

09.30 P04 : radionucleide therapy for primary liver tumors. 

B. lambert / UZ gent 

09.50 P05 : sIrt: Nuclear medicine considerations and pitfalls. 

P. flamen / UlB Bordet 

10.10 P06 : angiographic considerations in patients 

undergoing liver-directed therapies. 

g. Maleux / UZ leuven 

10.30 Discussion 


• 

sEssION 1: JOINT sEssION of radiology / BGdO / Nuclear Medicine society 

moDErators : P. sMEETs, C. VErsLyPE 

sEssION 2: JOINT session of BGdO / Pathology Club 

moDErators : I. BOrBaTh, C. CuVELIEr 

11.10 P07 a randomized phase II study of transarterial chemoembolization with 

doxorubicin eluting superabsorbent polymer microspheres in patients 

with hepatocellular carcinoma. 

h. Van Malenstein, g. Maleux, s. heye, V. Vandecaveye, W. laleman, J. Van Pelt, f. nevens, 

c. Verslype / kUleuven 

11.20 P08 Intraductal papillary mucinous tumor of the bile ducts 

k. Van den Bergh, d. Vanbeckevoort, d. Bielen, M. thijs, k. op de beeck, r. Vanslembrouck, 

f. claus, t. roland / kUleuven 


oom 


BgDo 

raDIology / 


11.30 P09 correlation between magnetic resonance imaging and pathological 

findings after neoadjuvant chemoradiation in rectal cancer. 

M. Mertens, c. sempoux, M. habay, f. Zech, a. kartheuser, P. scaillet, y. humblet, 

M. Van den eynde, e. danse, a. Jouret-Mourin / Ucl saint-luc 

11.40 P10 Dysplasia in fundic gland polyps: what to do? 

a. capoen, g. de hertogh, X. sagaert, e. Van cutsem, k. geboes / kUleuven 

11.50 P11 revision of a series of belgian hepatocellular adenoma according to 

the bordeaux experience. 

d. hoton (1), a. Jouret-Mourin (1), s. dardenne (1), c. hubert (1), J. gigot (1), J. rahier (1), 

g. cubel (1), s. godecharles (1), c. Balabaud (2), P. Bioulac- sage (2), c. sempoux (1) / 

[1] Ucl saint-luc, [2] University hospital Pellegrin, Bordeaux, france 

12.00 P12 : radionucleide therapy for Neuroendocrine tumors: 

indications and pitfalls. 

c. de roose / UZ leuven 

12.30 LuncH 

• 

sEssION 3: Joint session of Pathology Club and BGdO: Kras testing IN GI ONCOLOGy 

moDErators : E. VaN CuTsEM, P. PauWELs 

14.00 P13 : Emphasis on the key role of the pathologist in 

kras mutation testing in the selection of patients for Egfr-targeted 

therapy in colorectal cancer. 

a. hoorens (1), a. Jouret-Mourin (2), c. sempoux (2), g. de hertogh (3), P. demetter (4) / 

[1] VUB UZ Brussel, [2] Uclouvain, [3] kUleuven, [4] UlB erasme 

14.20 P14 kras mutation status in endoscopic and corresponding surgical 

biopsies of primary sporadic colorectal carcinoma. 

a. lemmens, X. sagaert, h. Prenen, k. geboes, s. tejpar, g. de hertogh / kUleuven 

14.30 P15 k-ras mutation detection by pyrosequencing in colorectal cancer. 

V. slachmuylder, a. Jouret-Mourin, M. heusterspreute, c. sempoux, J.l. gala / Ucl saint-luc 

14.40 P16 rapid and sensitive k-ras mutation detection by high resolution 

melting analysis and identification by pyrosequencing. 

P. Vannuffel, X. deghorain, J.l. dargent / institut de Pathologie et de génétique, gosselies 

14.50 P17 kras mutation detection using high resolution melting analysis and 

its prognostic value in paraffin-embedded formalin fixed colorectal 

cancer tissues. 

V. deschoolmeester (1), c. Boeckx (1), M. Baay (1), W. Wuyts (1), e. Van Marck (1), 

P. Vermeulen (2), P. Pauwels (1), f. lardon (1), J.B. Vermorken (1), M. Peeters (1) / 

[1] UZ antwerpen, [2] sint augustinus Ziekenhuis, antwerpen, 

15.00 P18 kras mutation status and colorectal cancer phenotype: is there a 

correlation? 

g. de hertogh, X. sagaert, k. geboes, a. tertychnyy / kUleuven 


31 

FrIday 5

FrIday 5 

room 


BgDo 

raDIology / 


15.10 P19 k-ras mutation in colorectal cancer: an one year experience. 

h. el housni, P. de Metter, B. dessars, P. heimann / UlB erasme 

15.20 round table : 

chairmen : E. Van Cutsem, P. Pauwels 

Pannel : A. Jouret-Mourin, Karel Geboes, P. Demetter, S. Tejpar and the speakers 


16.00 P20 faPa assocatIoN INvItED lEcturE : Diagnostic algorithm of 

lynch syndroom 

h. Vasen / leiden, the netherlands 

16.30 report of gI cancers symposium 2010, orlaNDo - BgDo 

Moderators: J.l. Van laethem, J. Janssens 

16.30 P21 oesophagogastric cancers: 

M. Van den eynde, Ucl saint-luc 

16.50 P22 Hepatobiliary and pancreatic cancers: 

c. Verslype, kUleuven 

17.10 P23 colorectal cancer: 

M. Peeters, UZa 



• 

room «tiffAnY» BsgI E / BEsPgHaN 

14.00 E01 foreign bodies extraction. 

P. Bontems / UlB hUderf 

14.20 E02 sedation and anesthesia in children. 

t. Pirotte / Ucl saint-luc 

14.40 E03 : Endoscopy for gErD in children. 

g. Veereman (1), i. hoffman (2) / [1] UZ antwerp, [2] kUleuven 

15.00 E04 Endoscopy for gErD in adults (including new techniques). 

d. de looze / UZ gent 

15.20 E05 Eus in pediatric population: indications, feasibility and impact on 

management. 

e. toussaint / UlB erasme 


• 

moDErators : P. VaN dEr sPEK, F. sMETs 

moDErators : P. dEPrEz, G. VEErEMaN 

16.00 E06 Bleeding in children: causes and endoscopic management. 

X. stephenne / Ucl saint-luc 

16.20 E07 New hemostasis techniques in adults. 

P. deprez / Ucl saint-luc 



33 

FrIday 5

FrIday 5 

room «cuLLinAn iii» NutrItIoN grouP 

• 

moDErators : J.C. PrEIsEr, d. ysEBaErT 

14.00 N01 Nutrition Day 2009 : Belgian results. 

J.c. Preiser (1) and k Boeykens (2) / [1] chU liège, [2] aZ sint-niklaas 

14.12 N02 Nutrition Day 2009: results from a cross-sectional nutritional risk 

screening on nineteen hospital wards. 

k. Boeykens / aZ sint-niklaas 

14.24 N03 utility and limitations of nutritional screening in a university hospital. 

e. de Waele, s. Mattens, k. delanghe, B. de Waele, g. delvaux / VUB UZ Brussels 

14.36 N04 the need for nutritional support in preoperative outpatients. 

B. geurden, a. Van Piggelen, n. delmotte, P. Van aken, d. ysebaert / UZ antwerpen 

14.48 N05 screening and predicting malnutrition in lung cancer patients: validation 

of new tools. 

n. Barthelemy, a.f. donneau, s. haterte, s. streel, a. albert, M. guillaume / Ulg 

15.00 N06 registration of nutritional parameters in paper based patient records at 

a university Hospital. 

B. geurden, c. Wouters, n. delmotte, P. Van aken, d. ysebaert / UZ antwerpen 

15.12 N07 risk of malnutrition in subjects older than 75 years in Belgium: 

results of Nutriaction. 

M. Vandewoude (2), a. Van gossum (1) / [1] VVkVM, sBnc, domus Medica, ssMg, 

[2] nutricia Belgium 


16.15 N08 Is early enteral nutrition dangerous in acute non-surgical colonic 

diverticulitis? 

g. Van ooteghem, h. rouviẽre, J.f. gallez, a. el nawar, a. nakad / chWapi notre dame, tournai 

16.27 N09 a dietary intervention with arabinoxylan oligosaccharides reduces 

colonic protein fermentation in healthy subjects: results from faecal 

metabolite fingerprint analysis. 

h. hamer, V. de Preter, l. cloetens, g. Vandermeulen, c. courtin, W. Broekaert, J. delcour, 

P. rutgeerts, k. Verbeke / kUleuven 

16.39 N10 augmenter les variétés des compléments médicaux oraux proposés 

(cmo) aux résidents de maisons de repos et maisons de repos et 

de soins influence-t-il l’adhésion à la prise de cmo, ainsi que l’état 

fonctionnel et la qualité de vie ? 

d. Brees / ch libramont 

16.51 N11 What can we learn from collecting data about the use of parenteral 

nutrition ? 

V. lievin, s. Vereecken, a. Ballarin, s. de Breucker, t. Pepersack, M. arvanitakis, J. Berre, 


17.03 N12 could we administer drugs along with parenteral nutrition? results of a 

survey.? 

a.Van gossum, a. Ballarin, V. lievin / UlB erasme 



www.rs-communication.be 

PM/PM/09/003/NF 

MAAGSAPRESISTENTE TABLETTEN - 20/40 MG 

COMPRIMÉS GASTRO-RÉSISTANTS - 20/40MG

FrIday 5 

13H00 -14H00 

• 

Joi nt m eeti ng: 

Poster session 

rEaDErs for a guIDED tour: M. arVaNITaKIs, P. PELCKMaNs 

D49 serum adiponectin strongly correlates with the degree of steatosis 

and inflammation but not fibrosis in a prospectively included cohort 

of NaflD patients. 

s. francque (1), a. Verrijken (1), i. Mertens (1), M.r. taskinen (2), g. hubens (1), e.Van Marck (1), 

P. Michielsen (1), l. Van gaal (1) / [1] UZ antwerpen [2] helsinki University central hospital and 

Biomedicum, finland 

D50 minimally invasive oesophagectomy: a valuable alternative to open 

oesophagectomy for the treatment of early oesophageal and 

gastro-oesophageal junction carcinoma. 

P. nafteux, J. Moons, W. coosemans, h. decaluwé, g. decker, P. de leyn, d. Van raemdonck, t. lerut 

/ kUleuven 

D51 Extent of liver resection in caroli’s disease: a multi-institutional 

retrospective study of 33 patients. 

c. hubert (1), J.y. Mabrut (2), c. Partensky (3), e. oussoultzoglou (4), d. Jaeck (4), J. Baulieux (2), 

o. Boillot (3), J. lerut (1), J.B. otte (1), J. de Ville de goyet (1), M. audet (3), c. ducerf (2), 

J.f. gigot (1) / [1] Ucl saint-luc, [2] la croix-rousse hospital, lyon, france, [3] hôpital edouard 

herriot, lyon, france, [4] hautepierre hospital, strasbourg, france 

D52 Is the use of Iv gadolinium mandatory in liver mrI for characterizing 

focal liver lesions as benign or malignant? 

M. antic (1), a. schiettecatte (1), d. Verdries (1), B. op de beeck (2), f. Vandenbroucke (1), 

s. dymarkowski (3), J. de Mey (1), M. dujardin (1) / [1] VUB UZ Brussels, [2] UZ antwerpen, [3] kUleuven 

D53 combined liver and kidney transplantation. 

t. serste (1), t. darius, d. Monbaliu, r. aerts, t. roskams, e. lerut, d. cassiman, c.Verslype, 

W. laleman, y. Vanrenterghem, f. nevens, J. Pirenne / kUleuven 

D54 liver transplantation for adult polycystic liver disease. 

t. darius (1), a. Patris (2), d. Monbaliu (1), e. Bonaccorsi (2), r. aerts (1), W. coosemans (1), 

t. roskams (1), Z. hassoun (2), o. ciccarelli (2), y. Pirson (2), y. Vanrenterghem (1), f. nevens (1), J. lerut 

(2), J. Pirenne (1) / [1] kUleuven, [2] Ucl saint-luc 

D55 a muticenter internal audit about following guidelines on osteoporosis 

prevention and detection in gI disease. 

d. Baert / Maria Middelares Ziekenhuis, gent 

D56 liver transplantation for hepatocellular failure after biliopancreatic 

diversion (scopinaro) or jejuno-ileal by-pass for weight reduction : 

a Belgian survey. 

a. geerts (1), t. darius (2), t. sablon (1), r. aerts (2), t. chapelle (3), g. roeyen (3), l. libbrecht (1), 

t. roskams (2), f. nevens (2), s. francque (3), J. Pirenne (2), r. troisi (1) / [1] Ugent, [2] kUleuven, 

[3] Uantwerp 

D57 laparoscopic cholecystectomy in acute cholecystitis: evidence to 

support a proposal for an early interval surgery 

k. Boterbergh, f. Berrevoet, i. adriaenssens, h. Peeters, e. de Wolf, B. Van den bossche, 

X. rogiers, B. de hemptinne, r. troisi, a. de croo / U gent 

D58 Wilson’s disease: long-term follow-up of a cohort of twenty-four 

patients treated with D-penicillamine. 

k. lowette, k. desmet, P. Witters, W. laleman, c. Verslype, f. nevens, J. fevery, d. cassiman / kUleuven 


BsGIE Meeting : Poster session 

D59 Weight reduction by means of an intragastric balloon in daily 

routine practice: results at removal and in long-term. 

e. cesmeli (1), h. troubleyn (2), M. daems (3), c. tuyttens (1), d. Vansteenkiste (1), t. onghena (1) / 

[1] aZ st. lucas, gent, [2] kUleuven, [3] st lucas, gent 

D60 the role of single-balloon endoscopy in diagnostics and minimally invasive 

treatment of patients with a clinical suspicion of obscure bleeding. 

e. ivanova, e. fedorov, M. timofeev, o. yudin, P. tcherniakevich / Moscow University hospital, 

Moscow, russia 

D61 single-balloon enteroscopy in patients with small bowel abnormalities. 

e. fedorov, e. ivanova, M. timofeev, o. yudin / Moscow University hospital, Moscow, russia 

D62 acute appendicitis after colonoscopy: an underevaluated complication? 

e. Vanderstraeten, d. Baert, e. Monsaert, k. rasquin, P. Burvenich / aZ Maria Middelares, gent 

D63 causes of non-resection of polyps during colonoscopy in hospitalized 

patients. 

M.a. denis, c. oxfort, k. azzouzi, o. dewit, h. Piessevaux, P. hoang, a. Uytterhoeven, P. deprez / 

Ucl saint-luc 

D64 Prospective comparison of full thickness resection of submucosal tumours 

with and without a new grasping device to help triangulation : the endolifter. 

P. deprez, J. navez, B. navez, J.f. gigot, e. legrand, P. gianello, c.P. yeung / Ucl saint-luc 

IBd Meeting : Poster session 

XXII 37 

nd D65 Differential mucosal expression of tH17 related genes in the small and 

large bowel of IBD patients. 

s. Bogaert, d. laukens, h. Peeters, M. lode, k. olievier, J. Vandesompele, d. elewaut, M. de Vos / Ugent 

D66 Defining endoscopic response in crohn’s disease. 

M. ferrante, M. noman, s. Vermeire, g. Van assche, P. rutgeerts / kUleuven 

D67 adalimumab improves work productivity for patients with 

moderately to severely active crohn’s disease: subgroup analysis 

of belgian patients in the care trial. 

e. louis (1), f. Baert (2), t.g. Moreels (3), g. d’haens (4), g. Van assche (5), o. dewit (6), M. devos (7), 

k. grosfils (8), n. chen (8), M. yang (8), P. Mulani (8), J. chao (8) / [1] Ulg, [2] hart hospital roeselare- 

Menen, roeselare, [3] UZ antwerp, [4] imelda gi clinical research centre, Bonheiden, [5] kUleuven, 

[6] Ucl saint-luc, [7] Ugent, [8] aBBott diagnostics 

D68 adalimumab for induction and maintenance of remission in 

anti-tNf–naïve and anti-tNf–exposed crohn’s disease patients 

in the care study: results from Belgium. 

e. louis (1), f. Baert (2), o. dewit (3), g. Van assche (4), g. d’haens (5), t. Moreels (6), a. robinson (7), 

M. kron (7), P. Pollack (7) / [1] Ulg, [2] heilig hartziekenhuis, roeselare, [3] Ucl, [4] kUleuven, 

[5] imelda gi clinical research centre, Bonheiden, [6] UZ antwerp, [7] aBBott 

D69 Impaired butyrate oxidation in ulcerative colitis is due to decreased 

butyrate uptake and a defect in the oxidation pathway. 

V. de Preter, g. Vandermeulen, P. rutgeerts, k. Verbeke / kUleuven 

D70 IBD and month of birth. 

J.M. ghilain, M. Vanderhofstadt, M. schapira, J.M. ghilain, o. descamps / hôpital de Jolimont, haine-saint-Paul 

D71 Plasma octanoylated ghrelin levels in young children with 

gastroesophageal reflux disease (gErD) and food refusal. 

e. dierckx (1), s. annemans (1), s. staelens (1), e. de Wever (1), i. depoortere (2), 

g. Veereman-Wauters (1) / [1] Queen Paola children’s hospital, antwerpen, [2] kUleuven 

• Belgian Week of gastroenterology • antWerP, March 4-6 2010 

FrIday 5

saTurday 6 

room «teun/LiJn» 

• 

ovEr aND uNDEr NutrItIoN 

08.50 Introduction: 

g. d’haens 

moDErators : J. CLOssET, h. VaN VLIErBErGhE 

sEvEN socI EtI Es 

symPosIum 

09.00 S01 gastrointestinal complications of overnutrition. 

i. leclercq / Ucl saint-luc 

09.25 S02 Bariatric surgery: from surgical techniques to metabolic changes. 

g. Präger / Vienna, austria 

09.55 S03 metabolic complications of bariatric surgery. 

a. geerts / UZ gent 

10.15 S04 Endoscopic treatment of obesity. 

P. swain / london, U.k. 


• 

moDErators : d. ysEBaErT, a. VaN GOssuM 

11.00 S05 should we still use diets in gastroenterology? 

e. Mathus-Vliegen / amsterdam, the netherlands 

11.25 S06 short bowel syndrome: from acute to chronic? 

W. Van gemert / Maastricht, the netherlands 

11.50 S07 role of nutritional support in cancer cachexia 

J.-M. argilés / Barcelona, spain 

12.15 S08 awards: 

12.50 LuncH 

- BWGE Basic and Clinical Awards 

- BGDO Award 

- IBD Prize 


oom «teun/LiJn» 

• 

moDErators : M. hIELE, M. sCaILLON 

sEvEN socI EtI Es 

symPosIum 

14.15 S08 anorexia Nervosa 

M. Vandewoude / tienen 

14.40 S09 Nutritional aspects of “Eras” (enhanced recovery after surgery) 

M. von Meyenfeldt / Maastricht, the netherlands 

15.05 S10 Nutritional aspects in liver diseases 

c. Verslype / kUleuven 

15.30 S11 PEg and PEJ-tubes: not only a technical procedure 

i. duysburgh / sint-niklaas 

15.55 S12 guidelines for the use of parenteral nutrition in gastroenterology 

(starting from case discussions) 


17.15 End of the symposium 


39 

saTurday 6

saTurday 6 

room 

«sAncY/tiffAnY» 

09.00 WElcomE 

• 

gI PatHology cluB: 

tHE PrEsIDENt’s Day 

«tIBI valE DIcImus» 

09.15 P24 Eosinophilic esophagitis versus reflux esophagitis. 

a. enzari / tUrQUey 

09.45 P25 Intestinal metaplasia in the endoscopic gastroesophageal junction 

versus short segment Barrett’s esophagus. 

J.f. flejou / france 

10.15 P26 gastric cancer and mimics of gastric cancer. 

f. carneiro / PortUgal 


11.00 P27 significance of IE lymphocytes in the small bowel. 

V. Villanacci / italy 

11.30 P29 zinc in gastrointestinal disease. 

g. faa / italy 

12.00 P28 two different views for a same lesion: Endoscopy versus Histology. 

g. lauwers / Usa 

12.30 LuncH 

• 

moDErators : P. dEPrEz, P. VaN EyKEN 

moDErators : a. drIEssEN, J.F. COLOMBEL 

14.00 P30 colitis mimicking IBD. 

n. shepherd / Uk 

14.30 P31 Dysplasia in IBD. 

B. riddell / canada 

15.00 P32 the perfect pathologist? an endoscopist’s vision. 

P. rutgeerts / BelgiUM 

15.30 P33 Pathologic predictors of microsatellite instability in colorectal cancer. 

J. greenson / Usa 

16.00 P31 conclusion 


BR 8593 - 01/2009

frIDay NIgHt Party 

at the « appelmans Brasserie » 

on Friday March 5, 2010 at 8.00pm 

Venue : Papenstraatje 1, 2000 antwerp 

The Belgian Week steering Committee is looking forward to 

welcoming all the registered participants and partners to the 

Friday Night Party ! 

The aperitive and dinner will take place at the «appelmans Brasserie 

and absinthbar» with delicious food, and nice music. Everything is 

there for an enchanting evening! 

Make sure to join us and register on the websites : 

www.belgianweek.be or www.bwge.be 

the appelmans Brasserie is at a walking distance (50 m) 

of the hilton hotel. 


43 


Thursday 4 

FrIday 5 

saTurday 6 

takE mE to HIltoN aNtWErP 

Itinerary 

address : 

hilton antwerp hotel 

groenplaats – 2000 antwerp 

tel: +32 3 204 12 12 

fax: +32 3 204 86 88. 

From antwerp Central station (max 10min) walking. 

1. Please leave the train station by the main entrance. 

2. follow the street in front of the main entrance, “de keyserlei” until you reach a big crossroad which 

you need to cross. 

3. follow the “Meir” (shopping street) on the other side until the end. 

4. at the end of the “Meir” you will see the “kBc” tower. 

5. cross the street on the right side of the “Meir” to reach the “eiermarkt”. 

6. follow the “eiermarkt” until the end where the main entrance of the hilton antwerp is. 

From antwerp Central station (max 10min) by tram. 

1. Please go to level -1 in the train station. follow the sign ‘M’ Metro 

2. Please take the tam 15 or 2, direction groenplaats 

3. get off the tram at station groenplaats 

4. follow the exit groenplaats shopping center 

5. you will arrive in the groenplaats Parking or on the groenplaats square 

6. follow the “eiermarkt” until the end where the main entrance of the hilton antwerp is. 

By car : 

Coming from Ghent (E17) 

1. immediately after the kennedytunnel take exit nr. 5a direction antwerpen centrum-Zuid. 

2. select the left lane and turn left at the traffic lights. 

3. again select the left lane and go straight ahead at the next traffic lights. 

4. after the flashing amber you see a big blue building on your left side. there you take the second street 

on your right (Vlaamse kaai). 

5. at the end of the Vlaamse kaai you turn right. 

6. at the fourth traffic light you turn right, this street is called ‘suikerrui’. 

7. on the suikerrui after the first traffic lights you take a very sharp turn to the right. 

8. in front of you you will see the hilton antwerp and the underground parking ‘groenplaats’. from the 

parking there is a direct connection to the hilton antwerp lobby. 


Coming from Eindhoven/hasselt (E34/E313) 

1. at the end of the e34/e313 you take the first exit 5a on the ring, direction antwerpen centrum Zuid 

(antwerp center south) 

2. select the left lane and turn left at the traffic lights. 

3. again select the left lane and go straight ahead at the next traffic lights. 

4. after the flashing amber you see a big blue building on your left side. there you take the second street 

on your right (Vlaamse kaai). 






Coming from Brussels (E19) 

1. in the craeybeckxtunnel take the left lane direction antwerpen centrum. 

2. at the traffic lights straight ahead (generaal lemanstraat). 

3. at the second traffic lights turn left (Jan van rijswijcklaan). 

4. at the next traffic lights turn right (lange lozannastraat). 

5. after the fourth traffic leights you cross the Boulevard and arrive in the kasteelpleinstraat. the road 

makes a left turn and becomes kronenburgstraat. follow this road. 

6. at the next traffic lights turn right (nationalestraat) 

7. go straight on. 

8. you arrive at the groenplaats. Please park your car in the car park groenplaats right in front of you. 

there is a direct access from the car park into the hotellobby. 

9. the main entrance of the hotel is on the eiermarkt. 

Coming from Brussels via Boom (a12) 

1. follow the a12 direction antwerpen. Before the tunnel choose the left lane direction 

antwerpen-centrum. 

2. Please follow direction antwerpen centrum – Zuid . 

3. see point 2 coming from gent. 

Coming from zelzate, Linkeroever 

1. follow the signs direction antwerpen 

2. take the Waaslandtunnel (under the schelde). right after you exit the tunnel make a sharp turn to 

the right this is the Vlaamse kaai. 






Coming from Breda (E19)/ Bergen op zoom (E34/a12) 

1. at the intersection antwerpen-noord you follow the a12 direction Bergen op Zoom. 

2. take exit 16 ekeren. 

3. at the traffic lights take left (noorderlaan) direction antwerpen – haven 1-100. 

4. you are now on the noorderlaan. 

5. follow this road for about 4.5km. 

6. at the end of the noorderlaan ( the road makes a turn of 45° on a bridge) you arrive at traffic lights. 

stay completely right. 

7. you arrive in the londonstraat, go straight ahead to the riverside. at the t crossing after the lights turn left. 

8. you are now on the riverside. 

9. turn left at the third traffic lights, suikerrui. straight ahead over the oude koornmarkt and the kammenstraat. 

10. at the first trafficlight take a sharp turn left on to the nationalestraat. you arrive at the groenplaats 

with the underground car park right in front of you. you have an immediate access from the car park 

into the hotellobby. 


45 


Thursday 4 

FrIday 5 

saTurday 6 

NotEs 


NotEs 


47 


www.astrazeneca.be 

a. lEgraND 

acErtys 

actIal farmacEutIca 

allErgaN 

BENEtEc 

BrIstol myErs sQuIBB 

BoPHar 

BostoN scIENtIfIc 

Boucart mEDIcal 

camPro scIENtIfIc 

cook mEDIcal 

DaNoNE 

D r f a l k P H a r m a 

BENEluX 

EccE 

EcHosENs 

ErBE 

EumEDIca 

fErrINg 

fIDEs mEDIcal 

fuJINoN - oNIs 

IPsEN 

JoHNsoN & JoHNsoN 

PartNErs 2010 

PrEMIuM ParTNErs 

M a J O r P a r T N E r 

rEGuLar ParTNErs 

mDs NorDIoN 

mEDvIsIoN BENEluX 

mENarINI 

movEtIs 

NorgINE 

NovartIs 

olymPus 

oraNgE mEDIcal 

orPHaN EuroPE 

P E N t a X - H I t a c H I 

D E B E u k E l a E r 

mEDIcal 

rms ENDoscoPy 

solvay PHarma 

t B s - B E t E l E m a t I c & 

BIomEDIcal sErvIcEs 

t I B o t E c - J a N s s E N 

cIlag 

t o s H I B a m E D I c a l 

systEms 

tramEDIco 

uEgW 2010 BarcEloNa 

yakult

Belgian Week of Gastroenterology

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?